Program

08:00 - 18:00 - REGISTRATION AND EXHIBITIONS OPENS

09:30 - 18:00 - PARTNERING ONE-TO-ONE MEETINGS

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
21:00
21:30
FINANCE & INVESTMENT PROGRAM
Italica Auditorium
FINANCE & INVESTMENT PROGRAM
Italica Auditorium
Finance your innovation through non-dilutive funding
10:00 - 11:00
Finance your innovation through non-dilutive funding
10:00 - 11:00

With the collaboration of:


Topics to be discussed: • What can CDTI do for R&D activities for biotechnology companies? • Supporting internationalization of biotech companies through technological cooperation. • Opportunities for biotechnology in Horizon 2020 - Horizon Europe. • Non-dilutive funding from US Federal Agencies and Private Foundations.

Chairperson:


Cecilia Hernández 
Head of Department -Health, Bioeconomy, Climate & Natural Resources.
CDTI -Centre for the Development of Industrial Technology  (Spain)

Physicist at Universidad Autonoma de Madrid. CSIC Instituto de Ciencia y Tecnología de Polimeros. Production and R&D departments at Private Company Joined CDTI in 1991. Different responsibilities : Spanish representative to several European Union Framework R&D Programmes as well as to the European Space Agency.

Speakers:


"NIH/DOD Non-Dilutive Funding Opportunities - Non-US Applicants Welcome"

Jonathan Adalist
Head of Business Development
Freemind Group (USA)

Jonathan Adalist, Head of Business Development at FreeMind, has been with the firm since 2014 and has comprehensive experience and an extensive understanding of the non-dilutive funding landscape in the US. Before joining FreeMind, Jonathan held various marketing and sales positions having done business in the US, Central and South America, Europe, and the Middle East. Jonathan holds a B.Sc. in Biology and an M.Sc. in Biotechnology and Molecular Biology from Tel-Aviv University.




“CDTI RTDI (Research, Technology Development and Innovation) funding Instruments”

Juan Luis Romera
Management, promotion & expert advice of R+D +i projects – Health. Department of Health, Bioeconomy, Climate and Natural Resources
CDTI -Centre for the Development of Industrial Technology  (Spain)

Juan Luis has more than 20 years of work experience, the last 12 years at CDTI. Before joining CDTI, Juan Luis has worked in different position: Toledo Hospital (Clinical Analysis Doctor (Practitioner)), in the pharmaceutical industry (as scientist at Johnson and Johnson Pharmaceutical Research and Development) and as researcher at University of Granada. Juan Luis holds a PhD in Organic and Pharmaceutical Chemistry from University of Granada.




"Opportunities for Biotechnology in Horizon 2020"

Marta Gómez
Spanish Representative in Horizon 2020 – Societal Challenge 1 Health, demographic change and wellbeing and in the Innovative Medicines Initiative (IMI)
CDTI -Centre for the Development of Industrial Technology  (Spain)

Biologist with a Master in Biotechnology (Business Administration for Biotech Companies). She has been working since 2003 for the Spanish Centre for the Development of Industrial Technology (CDTI), a public company within the Ministry of Science, Innovation and Universities; the Business Innovation Financing Agency. Marta’s work is fully dedicated to Horizon 2020 in the EU Programmes Division, being the Spanish Representative in Horizon 2020–Societal Challenge 1 Health, demographic change & wellbeing & in the Innovative Medicines Initiative (IMI), where she is the elected vice chair of the States Representatives Group since 2015.



“Regional public support for R & D in Andalusia”

José A. Pascual Sánchez
Head of Innovation and Programmes Unit
The Innovation and Development Agency of Andalusia (IDEA Agency)

Start-ups presentations
11:00 - 12:00
Start-ups presentations
11:00 - 12:00

11:00 - Ability Pharmaceuticals (Spain)
11:10 - Avivagen (Canada)
11:20 - Biohope (Spain)
11:30 - Bioquochem (Spain)
11:40 - Cristal Pharmaceuticals (Netherlands)
11:50 - Cannabiotics: exploring the antitumor effect of cannabinoids in hematologic malignancies - Institute of Biomedicine of Seville/University Hospital Virgen del Rocio(Spain)

Welcome remarks & institutional inauguration Italica Auditorium
12:00 - 13:00
Welcome remarks & institutional inauguration Italica Auditorium
12:00 - 13:00

Lunch Break
13:00 - 14:00
Lunch Break
13:00 - 14:00

Early Stage Financing & impact investment in biotechnology
14:15 - 15:15
Early Stage Financing & impact investment in biotechnology
14:15 - 15:15

Sponsored by:





The number of financing agreements and M&A in the early stages is increasing in the life sciences. Investing early is risky, but it also gives you the opportunity to build the asset in a very direct way.

Chairwoman:


“Keys to invest in early stage biopharma”

Clara Campàs Moya
Partner & co-founder
Asabys Partners (Spain)

Dr. Clara Campàs-Moya is partner and co-founder at the recently created venture capital firm ASABYS Partners (Barcelona). Formerly, she served as Strategy & Development Director at Kern Pharma (2014-2018) and as a managing director at Advancell. Dr. Campàs has served as a member of the Investment Committee of the venture capital firm HealthEquity, as well as vice-president of CataloniaBIO, and acts as a mentor in several programs such as d-Health MOEBIO, Caixaimpulse and the BCN Mentoring Program. Dr. Campàs-Moya is the co-author of the Acadesine patent (the first Spanish patent from a public University reaching clinical trials successfully). Up to 2006 Dr. Campàs-Moya was a researcher engaged in the development of new therapies in cancer. Dr. Campàs-Moya has published extensively in peer-reviewed scientific journals as well the medical literature. She received her Doctorate in Pharmacy in 2004 and a Master’s in Pharmacy from the University of Barcelona in 1999.

Speakers:

 

“Investing in ‘build’ vs. ‘growth”

Marco Boorsma
General Partner
Forbion Capital (The Netherlands)

Marco is General Partner at Forbion and has a key role in the investment team with focus on biopharma and a special interest to bring his background in molecular biology, operational and business development experience from both small and large businesses to the portfolio. He currently serves on the boards of several of Forbion portfolio companies, and was instrumental in starting-up, investing and the sale of recent portfolio companies such as NorthSea, Prexton, Dezima and Akarna.



“Funding Biotech companies in the early stages: Equity crowdfunding and co-investment with business angels and VCs”

Daniel Oliver
Director
Capital Cell (Spain)

Biology Degree, Universitat de Barcelona, specializing in Biomedical Sciences. Founder and CEO, Capital Cell (Europe’s 1st Life Sciences investment platform). President, Spanish Crowdfunding Association, between July 2014 and September 2016. Member of the European Stakeholders Forum. Advisor to the European Commission on alternative financing legislation since January 2015. Founding member and Board of Directors, European Equity Crowdfunding Association. Professor of entrepreneurship and business financing in Barcelona Activa.





“Public Funding in Andalusia”

Manuel Rodriguez
Project Manager
Venture Invercaria (Spain)


Since 2005,Manuel Rodriguez is Investment Director at INNOVA VENTURE SGECR, S.A., a public venture capital company owned by the Regional Government of Andalucia focused in early stages (seed and start-up), analyzing business plan of more than 500 companies, supervising and elaborating the evaluation documents and the proposal of investment definition, negotiating the shareholders' agreement and monitoring the investment from the Board of Directors. Graduated in Economics Universidad Complutense de Madrid.



“Maximizing investment value through Clinical Development Strategy”

José González Martínez
Associate Principal, Consulting Services
IQVIA (Spain)

José González is Associate Principal within IQVIA’s Strategic Consulting Team. He has a track record of more than 10 years and is specialized in advising companies in the Pharma and Biotech industries, valuation of investment opportunities in the health sector, long term corporate strategy and new market entry strategy. He holds a degree in Business Administration and environmental sciences from the Universidad Autónoma de Madrid and a MBA from Duke University.


Start-ups presentations
15:15 - 15:45
Start-ups presentations

15:15 - Tetraneuron (Spain)
15:25 - Vaxdyn (Spain)
15:35 - Versantis (Switzerland)

Plenary Session - Italica Auditorium Marta Alarcón Riquelme, Head-Area of Medical Genomics (Genyo)
15:45 - 16:15
Plenary Session - Italica Auditorium Marta Alarcón Riquelme, Head-Area of Medical Genomics (Genyo)

Marta E. Alarcón Riquelme
Head of Medical Genomics, Genyo (Spain)
Head Managing Entity PRECISESADS IMI Project



Towards the Re-clasification of the Systemic Autoimmune Diseases

Dr. Alarcón background is in Medicine with a PhD in Immunology at Stockholms University. From there Dr. Alarcón did her postdoctoral work at Uppsala University, In Sweden on the genetics of the autoimmune disease systemic lupus erythematosus until she became Full Professor in 2009. She also spent 6 years at the Oklahoma Medical Research Foundation (2009-2015) and since 2011 Dr. Alarcón has set up her laboratory in Spain, Granada at Genyo (Pfizer-University of Granada-Junta de Andalucia Centre for Genomics & Oncological Research).

Dr. Alarcon has identified several genes involved in the susceptibility to develop lupus, published in Nature Genetics (2002, 2006, 2008) and lately, with the PRECISESADS project we are working on the molecular reclassification of the systemic autoimmune diseases such as lupus, rheumatoid arthritis, scleroderma and Sjogren´s syndrome.

Big-Pharma presentations
16:30 - 17:00
Big-Pharma presentations

16:15 Johnson & Johnson



“External Innovation from Jonhon & Johnson”

Antonio Gomez
New Ventures Lead
Johnson & Johnson (Spain)

Antonio Gomez has almost 20 years of experience in the Pharma industry. Right before getting a PhD in Synthetic Organic chemistry from the University of Salamanca he joined the Janssen R&D group in Toledo as a medicinal chemist in 1996. In 2000 he spent one year in the Research Support group of Janssen Pharmaceutica at Beerse, Belgium. Then, he came back to Toledo, where he has held different positions coordinating first the internal projects, then the scientific IT with a special role in the development of the Janssen R&D Electronic Lab Notebook and, since 2012, the external collaborations. Starting in late 2013 this role has been integrated into the position of New Ventures Lead in Spain for the London Johnson & Johnson Innovation Center. As such he is in charge of scouting the Spanish scientific landscape and setting up collaborations in the country.

 
16:25 Eli Lilly and Company:

"BIC Cassette as a New Tool to Enable Novel Biological Targets"



Maria Angeles Martinez Grau
Senior Research Advisor, Medicinal Chemistry and External Innovation
Eli Lilly and Company (Spain)

Maria Angeles received her doctorate in Organic Chemistry from Universidad Complutense in 1994 and the “National Award for Young Investigators” (RSEQ) in 1995. After two years of postdoctoral research at the University of Pittsburgh, she became Associate Professor at Universidad Complutense. Maria Angeles joined Lilly in 1998 at the Spanish site and accepted an assignment for three years in Indianapolis. As medicinal chemist, she has contributed to deliver 12 clinical candidates in the areas of Neuroscience, Obesity and Diabetes. In 2017, she accepted the role of Coordinator of External Innovation in Europe in addition to her scientific responsibilities.

 
16:35 MSD

"Collaborating and partnering with MSD”

Phil L’Huillier
Head of Business Development, Europe & Middle East
MSD (United Kingdom)


16:45 Novartis Pharma AG

“Your partner of choice”

Begoña Carreno
WorldWide Head BD&L Respiratory
Novartis Pharma AG (Switzerland)

 

Corporate vs Private VC: differences, similarities & sinergies
17:00 - 18:00
Corporate vs Private VC: differences, similarities & sinergies
17:00 - 18:00

Sponsored by:


Funding options in the biotech sector have opened up, at the same time that new business models emerge. Venture Capital seems more and more interested in funding startups, and corporate investment rises as an investment model to boost their growth with a dedicated investment team that resides within the corporation. In the search of high-growth potential companies, do VC and Corporate investors look for the same type of companies? Which is the control level they look for? Which are the differences, similarities and synergies?


Chairperson:


María Jesús Fernández
Director of Finance and Investor Relations
ICEX-Invest in Spain Ministry of Industry, Commerce and Tourism (Spain)

Director of Finance & Investor Relations at ICEX-Invest in Spain, a position she took after having served as Trade Commissioner of Spain in Chicago for five years and Director General for International Financing at the Ministry of Economy and Finance for two years. During her extensive professional career, she has also held senior positions at the Bank of Spain, where she was Head of the International Relations Division and Head of the European Affairs Division; at the International Monetary Fund (IMF) and the World Bank, where she represented Spain at the Executive Board as Senior Advisor and Alternate Executive Director respectively; and at the Defense of Competition Tribunal, where she was Head of the President’s Office and Deputy Director of the Studies Department.  

Speakers:




"CVC funding - early stage appetite vs risk and company building"

Hakan Goker
Senior Investment Director
M Ventures (Netherlands)

Senior investment director at M Ventures, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan has been investing for the past 12 years and joined Merck Ventures in 2013. Previously Hakan was a partner at Aescap Venture and prior to that worked at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and corporate strategy of multiple biotechnology companies globally including Artios, Asceneuron, Storm, Bicycle, and F-star. Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital.




Giovanni Mariggi
Principal
Medicxi (United Kingdom)

Principal in the Medicxi investment team with main focus on growth stage clinical opportunities. Prior to joining Medicxi, Giovanni was a Principal with Index Ventures, having joined the firm in 2012. Before that he was at Cancer Research UK's London Research Institute (LRI; now the Crick Institute). At the LRI he conducted research focused on vascular biology and angiogenesis, whilst also delivering competitive intelligence projects to biopharmaceutical companies in the oncology field. Giovanni currently sits on the board of directors of Gadeta, SuperX, Kymo Therapeutics and Janpix.




Julien Michaux
Managing Director
Norgine Ventures (United Kingdom)

Julien Michaux joined Norgine Ventures from Lazard where as a member of the Healthcare M&A team he advised many European and US clients on merger and acquisition transactions. Julien joined Lazard in 2005 from J&J Pharmaceuticals where he worked as part of the M&A team. Julien has 11 years of experience in the Healthcare industry. He started his career with Procter & Gamble.




“Life science investing from an institutional VC´s point of view”

Stefan Luzi
Partner
Gilde Healthcare (The Netherlands)

Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical and life science instruments sectors. He led the investment in Lava Therapeutics B.V. and was part of several other investments. Stefan holds a MSc in Biotechnology degree from ETH Zurich (Switzerland) and a MPhil in Bioscience Enterprise degree from the University of Cambridge (UK). He also completed a PhD program with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK), where he developed a bicyclic peptide-based drug discovery platform.


 

Keith Blundy
Chief Executive
Storm Therapeutics (United Kingdom)

​CEO of the Cambridge cancer drug discovery start-up Storm Therapeutics and the former CEO of Cancer Research Technology (CRT). His experience covers ten years developing and commercialising plant biotechnology inventions and the last twenty years in cancer drug discovery and IP commercialisation. Whilst at CRT he established the CRT Pioneer Fund and was involved in forming companies such as Kudos, PIramed, Mission Therapeutics and GammaDelta Therapeutics. He is currently Chairman of Cizzle Biotechnology and on the board of Inivata.




Sergio Pérez
Managing Director Sabadell Venture Capital
Banco Sabadell Capital (Spain)

Sergio Pérez is an Investment Director at the Venture Capital division of Banco Sabadell. Sabadell Venture Capital , is Banco Sabadell´s initiative that directly provides equity and venture debt to early stage companies across Spain with a focus on ICT with a philosophy focused on supporting entrepreneurs. In addition, Sabadell Venture Capital has been carried out its presence in the healthcare investments, acting as an LP in funds and through direct co-investment agreements with these funds.

Welcome Reception (Location TBD)
19:00 - 21:30
Welcome Reception (Location TBD)
19:00 - 21:30

BREAKOUT SESSIONS
​Ronda Room
BREAKOUT SESSIONS
​Ronda Room
Is there a way out of the dementia maze?
10:45 - 11:45
Is there a way out of the dementia maze?
10:45 - 11:45

Sponsored by:


After 15 years of disappointing clinical trial results in AD and relatively little late stage clinical trial work in other dementias, are we perhaps looking in the wrong places? Much of the research has been very protein specific, especially amyloid and tau, but does these protein changes truly reflect pathology or are they markers of something else? Moving earlier in the described disease processes has brought very limited signs of success, partly perhaps due to the fact that placebo decline is so small at this stage. Neurodegeneration, synaptic loss and especially neuro-inflammation are now increasingly implicated in the dementia process and may have common mechanisms that can be explored. Can we tap in to these, especially with compounds with a more multimodal action? If so, this means adapting the disease modification ideal to something less specific and maybe defining what happens generally as the brain ‘fails’ and the impact we might have on that as a whole, rather than comparing averages in specific disease scales derived from population studies. The time has come for a challenging look at our hypotheses, methods and methodologies in dementia studies; in comparison with and alongside other complex conditions, such as cancer and heart disease. Our panel will highlight some of the issues and offer personal perspectives, after which there will be plenty of time for discussion. Our aim, collectively with the audience, is to disrupt the current thinking in order to develop new insights on how to find the pathway from where we can find our way out of the current dementia maze.

Chairperson:



Roger Bullock
Chief Medical Officer
Oryzon (Spain)


Since May 2017, Roger Bullock has been the Chief Medical Officer at Oryzon Genomics. He came to industry after nearly 30 years of academic clinical research in various neurological disorders, but especially Alzheimer’s disease. Trained initially as a psychiatrist, he has been involved in the development of all the current drugs available in AD and is overseeing the current Oryzon study in that area, among several others. Roger worked in the UK NHS for 30 years as well as conducting research. He has over 100 publications and continues to be an active international speaker.


  Speakers:


"Defeating dementia - what can we learn from other neurodegenerative disorders?"

Jina Swartz
​Therapeutic Area Head Neurosciences and Executive Medical Director, Global Clinical Development - EU
MSD (Merck and Co)(U.K.)


Dr Jina Swartz trained in Internal Medicine and Clinical Neurology in Johannesburg, South Africa, where she obtained her MBBCh (or MD) degree cum laude, followed by an MSc Medicine (in Neurology). She has a very broad-based clinical training obtained both in South Africa and the United Kingdom, having worked as a clinician in Internal Medicine, Neurology, Infectious diseases (with a particular emphasis on tropical diseases and HIV/AIDS), Paediatric surgery, Plastics Surgery and Psychiatry. Within the Neurology speciality, she has a special interest in neurodegenerative disorders (encompassing  dementias and movement disorders including Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, spinocerebellar degenerations), cerebrovascular disease, infectious Neurology (and HIV/AIDS), migraine, Paediatric Neurology and Neurogenetics. Following the award of a post-doctoral research fellowship in 1998, she completed a PhD at the University of Cambridge in the Department of Medical Genetics at the Cambridge Institute for Medical Research (CIMR). This research explored molecular mechanisms of neurodegeneration in cellular models of Huntington's disease.


"Enrichment and reducing the placebo response: disease modification and neuropsychiatric symptoms"

Clive Ballard
​Pro-Vice-Chancellor and Executive Dean & Professor of Age-related Diseases
The University of Exeter Medical School (U.K.)


Clive Ballard is part of a growing team of outstanding dementia researchers at the University of Exeter Medical School, which is recruiting high-calibre academics and expanding educational programmes and student numbers. In the last year, the Medical School has reached the Leiden ranking’s world top 30 for the quality of its Health and Biomedical Science research, attracted a £10 million donation from the Dennis and Mireille Gillings Foundation, launched a new Academy of Nursing and received permission to expand Medicine student numbers.

Clive is a world-renowned researcher who has led or co-authored well over 500 research papers. His main research specialisms are drug discovery, dementia prevention, improving care for people with dementia in residential homes, reducing prescribing of harmful antipsychotic drugs for people with dementia and researching more beneficial alternatives. He is also an expert in Lewy Body Dementia and Parkinson’s Disease Dementia, and is an advocate of better prescribing and treatment pathways to improve outcomes. Before joining Exeter, Clive held directorship roles at King’s College London Institute of Psychiatry and at the Alzheimer’s Society. He was pivotal in the successful campaign to overturn a NICE decision and make anti-dementia drugs available for people with dementia.

Welcome remarks & institutional inauguration Italica Auditorium
12:00 - 13:00
Welcome remarks & institutional inauguration Italica Auditorium
12:00 - 13:00

Lunch Break
13:00 - 14:00
Lunch Break
13:00 - 14:00

Milestones and Current Challenges in Advanced Therapies
14:15 - 15:45
Milestones and Current Challenges in Advanced Therapies
14:15 - 15:45

In collaboration with;


​This session will focus on the challenges in the development of Advanced Therapy Medicinal Products as well as in making these innovative products available to patients. Several examples from academia and industry will illustrate some milestones achieved and specific hurdles associated with cell, gene and tissue engineering products.
 

Chairperson:



Edwin Wagena
Chief Operating Officer
Rexgenero (UK)

Edwin Wagena was appointed as Chief Operating Officer of Rexgenero in April 2015. Edwin has close to 20 years of experience in pharmaceutical development both in academia and the pharmaceutical industry. He has strong knowledge and experience with the development of advanced-therapy medicinal products (ATMPs). Prior to Rexgenero, Edwin served as Chief Development Officer and Senior Vice President at Kiadis Pharma B.V. Between June 2014 and May 2016, Edwin was the Regional Vice-President Europe for the International Society for Cellular Therapy (ISCT). Edwin is an epidemiologist and received his M.A. in Health Sciences from the University of Groningen, the Netherlands. He obtained his Ph.D. in Medicine at the University Hospital Maastricht/Maastricht University, the Netherlands.

Speakers:



“Making ATMPs accessible to patients: the new Strategy and Action Plan of the Andalusian Initiative for Advanced Therapies”

Natividad Cuende 
Director
Andalusian Initiative for Advanced Therapies (Spain)

Natividad Cuende is the Executive Director of the Andalusian Initiative for Advanced Therapies since its creation in 2008 by the Regional Government of Andalusia. She is also the Deputy Director of the Andalusian Transplant Coordination since 2005 and previously she worked at the National Transplant Organization for over 7 years. Degree of MD and PhD, she is specialist on Family and Community Medicine as well as on Preventive Medicine and Public Health after 6 years as resident physician at different hospitals. She is the Director of the International Master Degree in Manufacturing of Advanced Therapy Medicinal Products and has published more than 150 scientific and technical publications. She is the Chair of the European Legal and Regulatory Affairs Committee of the International Society for Cell and Gene Therapy (ISCT) since 2014 and she also participates on several scientific committees and in multiple expert working groups.


“Exploring the role of IPS-derived retinal pigment epithelial (RPE) cells for generating advanced therapies for patients with Age-related macular degeneration (AMD)”

Francisco Javier Diaz-Corrales
Department of Cell Therapy & Regenerative Medicine
Andalusian Centre of Molecular Biology & Regenerative Medicine - CABIMER (Spain)


“Mesenchymal Stromal Cells: Current Limitations and Future Developments”

Massimo Dominici
Head of the Laboratory of Cellular Therapies
University Hospital of Modena (Italy)


“Personalized tissue engineered grafts – a specialty within a specialty area”

Raimund Strehl
Chief Technology Officer
Verigraft (Sweden)

Plenary Session - Italica Auditorium Marta Alarcón Riquelme, Head-Area of Medical Genomics (Genyo)
15:45 - 16:15
Plenary Session - Italica Auditorium Marta Alarcón Riquelme, Head-Area of Medical Genomics (Genyo)

Marta E. Alarcón Riquelme
Head of Medical Genomics, Genyo (Spain)
Head Managing Entity PRECISESADS IMI Project



Towards the Re-clasification of the Systemic Autoimmune Diseases

Dr. Alarcón background is in Medicine with a PhD in Immunology at Stockholms University. From there Dr. Alarcón did her postdoctoral work at Uppsala University, In Sweden on the genetics of the autoimmune disease systemic lupus erythematosus until she became Full Professor in 2009. She also spent 6 years at the Oklahoma Medical Research Foundation (2009-2015) and since 2011 Dr. Alarcón has set up her laboratory in Spain, Granada at Genyo (Pfizer-University of Granada-Junta de Andalucia Centre for Genomics & Oncological Research).

Dr. Alarcon has identified several genes involved in the susceptibility to develop lupus, published in Nature Genetics (2002, 2006, 2008) and lately, with the PRECISESADS project we are working on the molecular reclassification of the systemic autoimmune diseases such as lupus, rheumatoid arthritis, scleroderma and Sjogren´s syndrome.

Biobanks: structures at the service of research
16:15 - 17:00
Biobanks: structures at the service of research
16:15 - 17:00

Biobanking has become an important resource for healthcare research, medical care, and drug discovery. The kinds of questions being addressed in contemporary medical research depend upon the availability of biological tissue samples along with associated clinical data including medical, ´omics, genealogical, and lifestyle information. International awareness of the need for biobanks has increased, in part, because of the growing promise of research related to the development of personalized medicine, especially in oncology. Identification of biomarkers that are specifically associated with particular medical conditions such as cancer, cardiovascular disease, rare diseases and neurological disorders, among others, are useful for early detection, prevention, and treatment of the diseases. The ability to determine individual biomarkers and to use those biomarkers for disease diagnosis, prognosis and prediction of response to therapy is having a very significant impact on personalized medicine and is rapidly changing the way clinical care is conducted.

As a critical requirement for personalized medicine is the availability of a large collection of patient samples with well annotated patient clinical and pathological data, biobanks thus play an important role in personalized medicine advancement. Identification and validation of disease-relevant biomarkers is essential to developing diagnostic, prognostic, and therapeutic applications that will improve community health and protect the public from illnesses. For these purposes, high-quality and well-annotated tissue sample collections housed in specialized bio-repositories must be available.

The most important aspects of a biobank are consistency and quality. The validity of the data generated by biobanked samples depends on their quality, which is in turn dependent on the use of stringent standards in collecting the biospecimens and delineating patient characteristics. Variations associated with collecting, processing and storing different samples and the accompanying clinical data, make it extremely difficult to extrapolate or to merge data from different studies. Therefore, the standardisation and harmonisation of biobanking practices are of paramount importance.

The need for data grows strongly. It demands the gathering and administration of large collections of samples and related data, often from multiple sources. Hence, ‘virtual biobanks’ started forming with international collaboration and geographically distributed forms of endeavour.

Although researchers worldwide recognize European biobanks as important resources, obstacles to their efficient use exist. Critical points are the fragmentation of sample collections and a lack of harmony among technical, ethical, and legal requirements.

Data sharing across biobanks and research programs will be very important in the future of medical research to better understand individual differences in disease development, progression of disease, and response to treatment. Enabling such data sharing while protecting the privacy of individual research participants is a major challenge for the future. Biobanks will need to address data standards, metadata requirements, data quality, and how data are stored and accessed.

​ Challenges mentioned above and the impact of collaborative biobanking infrastructures in the framework of Horizon 2020 and beyond will be discussed.

Chairperson:

Manuel Rodríguez: Scientific
Director
Andalusian Public Health System Biobank (SSPA) (Spain)

Speakers:

Cristina Villena
Coordinator
National Biobanks Network Platform - PRNB (Spain)

Victor González
R&D Director
​Atrys Health (Spain)
Francesco Florindi
Engagement Officer
BBMRI-ERIC (Austria)

Biobanks: structures at the service of research
16:15 - 17:00
Biobanks: structures at the service of research
16:15 - 17:00

Biobanking has become an important resource for healthcare research, medical care, and drug discovery. The kinds of questions being addressed in contemporary medical research depend upon the availability of biological tissue samples along with associated clinical data including medical, ´omics, genealogical, and lifestyle information. International awareness of the need for biobanks has increased, in part, because of the growing promise of research related to the development of personalized medicine, especially in oncology. Identification of biomarkers that are specifically associated with particular medical conditions such as cancer, cardiovascular disease, rare diseases and neurological disorders, among others, are useful for early detection, prevention, and treatment of the diseases. The ability to determine individual biomarkers and to use those biomarkers for disease diagnosis, prognosis and prediction of response to therapy is having a very significant impact on personalized medicine and is rapidly changing the way clinical care is conducted.

As a critical requirement for personalized medicine is the availability of a large collection of patient samples with well annotated patient clinical and pathological data, biobanks thus play an important role in personalized medicine advancement. Identification and validation of disease-relevant biomarkers is essential to developing diagnostic, prognostic, and therapeutic applications that will improve community health and protect the public from illnesses. For these purposes, high-quality and well-annotated tissue sample collections housed in specialized bio-repositories must be available.

The most important aspects of a biobank are consistency and quality. The validity of the data generated by biobanked samples depends on their quality, which is in turn dependent on the use of stringent standards in collecting the biospecimens and delineating patient characteristics. Variations associated with collecting, processing and storing different samples and the accompanying clinical data, make it extremely difficult to extrapolate or to merge data from different studies. Therefore, the standardisation and harmonisation of biobanking practices are of paramount importance.

The need for data grows strongly. It demands the gathering and administration of large collections of samples and related data, often from multiple sources. Hence, ‘virtual biobanks’ started forming with international collaboration and geographically distributed forms of endeavour.

Although researchers worldwide recognize European biobanks as important resources, obstacles to their efficient use exist. Critical points are the fragmentation of sample collections and a lack of harmony among technical, ethical, and legal requirements.

Data sharing across biobanks and research programs will be very important in the future of medical research to better understand individual differences in disease development, progression of disease, and response to treatment. Enabling such data sharing while protecting the privacy of individual research participants is a major challenge for the future. Biobanks will need to address data standards, metadata requirements, data quality, and how data are stored and accessed.

​ Challenges mentioned above and the impact of collaborative biobanking infrastructures in the framework of Horizon 2020 and beyond will be discussed.

Chairperson:

Manuel Rodríguez: Scientific
Director
Andalusian Public Health System Biobank (SSPA) (Spain)

Speakers:

Cristina Villena
Coordinator
National Biobanks Network Platform - PRNB (Spain)


Victor González
R&D Director
​Atrys Health (Spain)

Francesco Florindi
Engagement Officer
BBMRI-ERIC (Austria)

Biobanks: structures at the service of research
16:15 - 17:00
Biobanks: structures at the service of research
16:15 - 17:00

Biobanking has become an important resource for healthcare research, medical care, and drug discovery. The kinds of questions being addressed in contemporary medical research depend upon the availability of biological tissue samples along with associated clinical data including medical, ´omics, genealogical, and lifestyle information. International awareness of the need for biobanks has increased, in part, because of the growing promise of research related to the development of personalized medicine, especially in oncology. Identification of biomarkers that are specifically associated with particular medical conditions such as cancer, cardiovascular disease, rare diseases and neurological disorders, among others, are useful for early detection, prevention, and treatment of the diseases. The ability to determine individual biomarkers and to use those biomarkers for disease diagnosis, prognosis and prediction of response to therapy is having a very significant impact on personalized medicine and is rapidly changing the way clinical care is conducted.

As a critical requirement for personalized medicine is the availability of a large collection of patient samples with well annotated patient clinical and pathological data, biobanks thus play an important role in personalized medicine advancement. Identification and validation of disease-relevant biomarkers is essential to developing diagnostic, prognostic, and therapeutic applications that will improve community health and protect the public from illnesses. For these purposes, high-quality and well-annotated tissue sample collections housed in specialized bio-repositories must be available.

The most important aspects of a biobank are consistency and quality. The validity of the data generated by biobanked samples depends on their quality, which is in turn dependent on the use of stringent standards in collecting the biospecimens and delineating patient characteristics. Variations associated with collecting, processing and storing different samples and the accompanying clinical data, make it extremely difficult to extrapolate or to merge data from different studies. Therefore, the standardisation and harmonisation of biobanking practices are of paramount importance.

The need for data grows strongly. It demands the gathering and administration of large collections of samples and related data, often from multiple sources. Hence, ‘virtual biobanks’ started forming with international collaboration and geographically distributed forms of endeavour.

Although researchers worldwide recognize European biobanks as important resources, obstacles to their efficient use exist. Critical points are the fragmentation of sample collections and a lack of harmony among technical, ethical, and legal requirements.

Data sharing across biobanks and research programs will be very important in the future of medical research to better understand individual differences in disease development, progression of disease, and response to treatment. Enabling such data sharing while protecting the privacy of individual research participants is a major challenge for the future. Biobanks will need to address data standards, metadata requirements, data quality, and how data are stored and accessed.

​ Challenges mentioned above and the impact of collaborative biobanking infrastructures in the framework of Horizon 2020 and beyond will be discussed.

Chairperson:

Manuel Rodríguez: Scientific
Director
Andalusian Public Health System Biobank (SSPA) (Spain)

Speakers:

Cristina Villena
Coordinator
National Biobanks Network Platform - PRNB (Spain)


Victor González
R&D Director
​Atrys Health (Spain)



Francesco Florindi
Engagement Officer
BBMRI-ERIC (Austria)

Biobanks: structures at the service of research
16:15 - 17:15
Biobanks: structures at the service of research
16:15 - 17:15

Sponsored by:



The most important aspects of a biobank are consistency and quality. The validity of the data generated by biobanked samples depends on their quality, which is in turn dependent on the use of stringent standards in collecting the biospecimens and delineating patient characteristics. Variations associated with collecting, processing and storing different samples and the accompanying clinical data, make it extremely difficult to extrapolate or to merge data from different studies. Therefore, the standardisation and harmonisation of biobanking practices are of paramount importance. The need for data grows strongly. It demands the gathering and administration of large collections of samples and related data, often from multiple sources. Hence, ‘virtual biobanks’ started forming with international collaboration and geographically distributed forms of endeavour. Although researchers worldwide recognize European biobanks as important resources, obstacles to their efficient use exist. Critical points are the fragmentation of sample collections and a lack of harmony among technical, ethical, and legal requirements.

Chairperson:

“Biobank network: from specimen to big-data”

Manuel Rodríguez
Scientific Director
Andalusian Public Health System Biobank (SSPA) (Spain) 

Speakers:

“Activity and services of Spanish National Biobank Network”



Cristina Villena
Coordinator
National Biobanks Network Platform - PRNB (Spain)

Cristina Villena Portella, PhD is the biobank manager of Pulmonary Biobank Consortium CIBERES (CIBER-ISCIII) since 2008 and, from 2018, also coordinator of the Spanish Biobank Network (ISCIII) formed by 39 biobanks, whose aim is improving Biomedical R&D through the access to standardized and well-characterized human biological samples for researchers and biotechnological companies.

Since 2015 she started the coordination of a biospecimen research line with the participation of 17 biobanks in Spain, getting in 2016 a multi-center project to develop the goals of this research line. The preliminary results have been published in several meetings, and getting some international prizes.

 
“Personalised medicine needs biobanking: is the biobanking community ready?”



Francesco Florindi
Engagement Officer
BBMRI-ERIC (Austria)

In BBMRI-ERIC, Francesco is responsible to coordinate the Stakeholder Forum, the main interface for European patients’ organisations, civil society, industry and academia to interact with the biobanking universe. Furthermore, Francesco helps raising awareness regarding the needs and expectations of the biobanking community towards the European Union, nurturing and maintaining relationships with the European institutions.

 


Víctor González
R&D Director
Atrys Health (Spain)

Director of R+D Department at ATRYS HEALTH. PhD. MSc. Dr González-Rumayor obtained his PhD in Genetics from University Complutense of Madrid. He has developed his career in the following positions: Scientific Director of Super Seed Biotech SA (SME); Professor of Biotechnology at Universidad de Segovia; Director of Innovation Circle of Biotechnology at Parque Científico de Madrid; Senior Researcher in Regenerative Medicine and Advanced Therapies at Health Institute Carlos III; Director of Programs a t Direccion General de Terapias Avanzadas y Trasplantes. Health Ministery; Counselor at Ministry of Health. Government representative at Policy and Coordinating Committee for Human Reproductive Health and Research (WHO)

Big Data & Biomedical Research
17:15 - 18:00
Big Data & Biomedical Research
17:15 - 18:00

Sponsored by:


In the last years, the capacity that new technologies offer us for the treatment of information has opened a new scenario of possibilities inconceivable some years ago. These new technologies and solutions, under the name of BigData, allow us to work with huge volumes of information of different nature and format, and treat it at a speed and with a level of veracity, not possible in our recent past. The applications in the field of health are potentially huge, for the detection of patterns of disease evolution, simulation of behaviors, development of prediction algorithms. However, given the nature of the information treated, all this must be compliance with the regulations on the matter, very recently updated with the GPDR.

Chairperson:



Juan Lucas Retamar Gentil
Deputy Director of Information Technology and Communications
SAS - Andalusian Health Service (Spain)

Industrial Engineer at Seville University, specialized in business administration, he completed studies at the INSA (National Institute of Applied Sciences) in Lyon. He first worked at Telvent (Abengoa group) four years as Project Manager in the Health ICT area, where he specialized in projects of digitalization of medical images. From Telvent he jumps to the Andalusian Health Service, where he develops his career the last thirteen years, successively holding posts of Technician (specialized in medical imaging), Head of Department in a medium hospital in Huelva (Hospital Juan Ramón Jiménez), CIO in a big hospital in Sevilla (Hospital Virgen Macarena, more than 5.000 employees) where he leads the complete transformation of the centre, and finally, CIO of the Andalusian Health Service for the last four years. From this role, he is responsible for different areas of competence and vertical field of technology, systems and infrastructure, support and maintenance of information systems, support user station, service user, etc ... for all public health centres at Andalucía system. In these years, Juan Lucas has made a deep reorganization of the TIC structure of the SAS, moving from small teams linked to centres, to a regional structure based on provincial teams dependent on the regional direction.

Speakers:



"Deep Learning applied to electronic health records"

Kazem Rahimi
Director, Deep Medicine Program
University of Oxford (U.K.)

Associate Professor of Cardiovascular Medicine at the University of Oxford. He is a cardiologist, epidemiologist and health services researcher with interest in prevention and management of chronic diseases. He has led the design, coordination and reporting of multi-centre randomized trials, collaborative meta-analyses and large-scale observational studies that have investigated the burden, causes and management of cardiovascular diseases. He is the Director of the Oxford Martin programme on Deep Medicine which is using some of the largest and most complex biomedical datasets that have ever been collected to generate insights into complex disease patterns, risk trajectories and treatment effects.

 


“Smart Knowledge Management for Healthcare”

Jorge Laguna Fanlo
Head of Smart Knowledge Management
Everis (Spain)

  Bachelor in Economic and Business Sciences, Postgraduate in Computer Engineering and PDD Master by IESE.
He started his career in computer consulting 20 years ago at CEMEX (Madrid) and later at ATCA (Technical Association of Savings Banks) and at Net2You in Zaragoza. He has combined his technological experience with banking management, being responsible for Operational Risk in CAI Savings Bank and in the area of Management Information Systems of Ibercaja Bank. He is currently the head of the Knowledge Management Office at everis and leading the development of advanced analytics solutions for healthcare.




“Andalusian Public Health System Population Health Database”

Francisco José Sanchez Laguna
Head of the Health Information Systems Coordination Department
SAS - Andalusian Health Service (Spain)

Francisco Sánchez Laguna is currently the head of the Information Systems Coordination Unit at the Andalusian Health Service since 2014. Previously he has been Deputy Chief Medical Officer at University Hospital Reina Sofia (Cordoba, Spain) for 4 years (2007-2011), leading most eHealth projects within the hospital. He was also responsible of the outpatients and diagnostic areas as well as the coordination with primary care.

 


Ignacio Hernández Medrano
CEO
Savana Medical (Spain)

Dr Medrano is a neurologist at Hospital Ramon y Cajal in Madrid. He is also the co-founder & CEO at Savana (Transforming healthcare through Artificial Intelligence) and the co-founder & CMO at Mendelian (Democratizing genomics in healthcare). Dr Medrano specialises in digital health, IT, entrepreneurship, innovation, education and research management as well as health information systems, quality systems and neurology.

Welcome Reception (Location TBD)
19:00 - 21:30
Welcome Reception (Location TBD)
19:00 - 21:30

BREAKOUT SESSIONS
Bahia Room
BREAKOUT SESSIONS
Bahia Room
Agrobiotechnology forum
10:00 - 12:00
Agrobiotechnology forum
10:00 - 12:00

10:00 - 10:15 PART 1. INTRODUCTION

10:15 - 11:00  PART 2. CHALLENGES IN THE AGROFOOD INDUSTRY



Challenges for Crop Biotechnology in Europe

Graham Brookes
Agricultural Economist
PG Economics Ltd (UK)

Graham is an agricultural economist and consultant with more than 30 years’ experience of examining economic issues relating to the agricultural and food sectors.  He is a specialist in analyzing the impact of technology, policy changes and regulatory impact.  He has, since the late 1990s, undertaken a number of research projects relating to the impact of agricultural biotechnology and written widely on this subject in peer reviewed journals.  This work includes annual updates of a global economic and environmental impact of GM crops report, the impact of insect resistant maize in Spain and herbicide tolerant soybeans in Romania, the impact of GMO labelling and ‘GMO avoidance’ in Europe, the economic impact of GMO zero tolerance legislation in the EU, the cost to the UK economy of failure to embrace agricultural biotechnology, the economic impact of bio-safety legislation in Turkey and studies of the potential impact of using crop biotechnology in the Ukraine, Russia, Thailand, Indonesia and Vietnam.
 
Paco Egea
Vice Chancellor of Research, Development and Innovation
University of Almeria (Spain)


11:00 -11:45  - PART 3. BIOTECHNOLOGY SOLUTIONS FOR THE AGROALIMENTARY INDUSTRY



Current and future biotechnological tools applied to plant breeding

Jordi García-Mas
Plant and Animal Genomics Program
Center for Research in Agricultural Genomics – CRAG (Spain)

PhD in Biochemistry and Molecular Biology at the Universitat Autònoma de Barcelona (1994) and Marie Curie postdoctoral fellow at the Sainsbury Laboratory (Norwich, UK) (1995-1997) in plant genetics. Since 1997, he is an IRTA researcher and in 2011 he joined the Plant and Animal Genomics Program at the Center for Research in Agricultural Genomics CSIC-IRTA-UAB-UB (CRAG). He is co-author of 76 publications in international peer-reviewed journals. Among other projects, he has coordinated the sequencing of the melon genome (MELONOMICS). He has contrasted experience in the transfer of genetic and genomic tools that are used in breeding programs by seed companies. He has participated in several national and international evaluation panels, regularly teaches in Master and Degree courses and has supervised 7 PhD theses.

 



Eduardo Díaz
Environmental Microbiology Group
Center of Biological Research, CSIC (Spain)

Dr. Eduardo Díaz obtained his PhD in Biology at the Complutense University of  Madrid (Spain) in 1991. Following the award of a post-doctoral research fellowship from 1992-1995 he worked at the National Center for Biotechnology (GBF) in Braunschweig (Germany) in the field of environmental microbiology. Since 1999 he is scientific researcher of the CSIC at the Biological Research Centre in Madrid, where he is currently heading the Environmental Microbiology group at the Microbial and Plant Biotechnology Department. He has more than 100 publications in international research journals on the genetics and molecular aspects of the biodegradation/bioconversion of contaminants in bacteria, as well as on the engineering of recombinant biocatalysts for biotechnological purposes. He has teaching experience supervising 14 PhD theses and 7 Master Degrees, and he has been member of several scientific committees of international congresses and selection committees of national research projects.
 


Functional foods, health claims and personalization

Andreu Palou
Director of the Laborarory of Molecular Biology, Nutrition and Biotecnology
University of the Balearics Islands (Spain)

Andreu Palou is Professor of Biochemistry and Molecular Biology at the University of the Balearic Islands (UIB). Head of the Laboratory of Molecular Biology, Nutrition and Biotechnology of the UIB and of the research group "Nutrigenómica y Obesidad" of CIBEROBN (Centro de Investigaciçon Biomédica en Red sobre Obesidad y Nutrición). Author of more than 350 scientific articles and several patents. He has been Vice-president of the Scientific Nutrition Panel of the European Food Safety Authority (EFSA) and vice-president and member of the Scientific Committee on Food. He was the first president of the Scientific Committee of the Spanish Agency for Food Safety and Nutrition (AESAN, actually AESAN) (2003-2010). He has received several awards, including the DuPont Science Award (2014). More information (CV) at: http://palou.uib.es/Andreu-Palou/


Dolores Corella
Department of Preventive Medicine and Public Health
University of Valencia & Tufts University (Spain)

Welcome remarks & institutional inauguration Italica Auditorium
12:00 - 13:00
Welcome remarks & institutional inauguration Italica Auditorium
12:00 - 13:00

Lunch Break
13:00 - 14:00
Lunch Break
13:00 - 14:00

Foodbiotech & Bioprocess
14:15 - 15:15
Foodbiotech & Bioprocess
14:15 - 15:15

Speakers:



Ricardo Ortiz
Business Manager
Rijk Zwaan (Spain)

Ricardo Ortiz, has a proven executive management track record and over 20 years of experience driving sales growth and marketing activities in the seed industry as Business Manager of Rijk Zwaan Ibérica, where he leads the implementation of all sales and marketing strategies in the Cluster formed by Spain, Portugal and Morocco countries, making his managerial responsibilities compatible with the coordination of the global pepper development.

Rijk Zwaan is amonst the top 5 vegetable breeding companies in the world. The focus is fully on vegetable seeds and offer a wide assortment within the sector.




"Innovations in quality & safety of fresh-cut produce"

Giancarlo Colelli
Professor, Department of Agriculture, Food and Environmental Sciences
University of Foggia (Italy)

Full Professor of Equipments for Postharvest Operations at the University of Foggia, Italy, where he also chairs the Doctorate Program on “Innovation Management in Agricultural and Food Systems of the Mediterranean Region”. R&D activities at the University of Foggia primarily include equipment implications on quality of whole and of fresh-cut fruits and vegetables, non-destructive technology for assessment of quality attributes in fresh fruits and vegetables, low impact technologies to extend the shelf-life of fresh fruits and vegetables. As principal investigator he has coordinated more than 20 national and International R&D Projects. In conjuction with other colleagues organized all editions of the European Short-course on Quality & Safety of Fresh-cut Produce (in Italy, Spain, Germany, Turkey, UK; next edition in Portugal). He is author of more than 200 scientific papers on national and international journals and proceedings.

Increasing the value of your Asset: considerations for Phase I hybrid trials
15:15 - 15:45
Increasing the value of your Asset: considerations for Phase I hybrid trials

Sponsored by:


This presentation will highlight the importance of gaining efficacy data early in clinical development and describe how Covance’s approach to hybrid Phase I study designs enables you to add value by inclusion of patients earlier in development. This multidisciplinary approach driven by scientific and medical insight will be illustrated by recent case histories in different therapeutic areas.

Speaker:


Amitava Ganguli
Medical Director, Medical & Scientific Affairs
Covance (UK)

>15 years of experience in clinical research and internal medicine. >10 years as an investigator in both healthy volunteers and patients in phase I to IV. PI for renal impairment patient trials. Medical Director roles at 3 MHRA accredited phase I units in the UK. Certified in Clinical Pharmacology and General Internal Medicine; Honorary Senior Lecturer in Clinical Pharmacology and Therapeutics at University of Liverpool.

Plenary Session - Italica Auditorium Marta Alarcón Riquelme, Head-Area of Medical Genomics (Genyo)
15:45 - 16:15
Plenary Session - Italica Auditorium Marta Alarcón Riquelme, Head-Area of Medical Genomics (Genyo)

Marta E. Alarcón Riquelme
Head of Medical Genomics, Genyo (Spain)
Head Managing Entity PRECISESADS IMI Project



Towards the Re-clasification of the Systemic Autoimmune Diseases

Dr. Alarcón background is in Medicine with a PhD in Immunology at Stockholms University. From there Dr. Alarcón did her postdoctoral work at Uppsala University, In Sweden on the genetics of the autoimmune disease systemic lupus erythematosus until she became Full Professor in 2009. She also spent 6 years at the Oklahoma Medical Research Foundation (2009-2015) and since 2011 Dr. Alarcón has set up her laboratory in Spain, Granada at Genyo (Pfizer-University of Granada-Junta de Andalucia Centre for Genomics & Oncological Research).

Dr. Alarcon has identified several genes involved in the susceptibility to develop lupus, published in Nature Genetics (2002, 2006, 2008) and lately, with the PRECISESADS project we are working on the molecular reclassification of the systemic autoimmune diseases such as lupus, rheumatoid arthritis, scleroderma and Sjogren´s syndrome.

New therapeutic approaches in ophthalmology
16:15 - 17:15
New therapeutic approaches in ophthalmology
16:15 - 17:15

Sponsored by:



Over the past years there have been considerable advances in the understanding of the pathogenesis of ophthalmic disorders. This knowledge is being translated to the drug discovery field. A variety of therapeutic approaches like advanced therapies, RNA interference technologies and new peptides will be discussed during the session with a special focus on their future impact in the treatment of severe unsolved diseases.

Chairperson:



Andres G. Fernández
Director
Ferrer Advanced Biotherapeutics (Spain)

PhD (Pharmacology; Univ. Barcelona) and MS (Pharmacy Spec. Biochemistry; Univ. Barcelona). Current position: Director of Ferrer Advanced Biotherapeutics at Ferrer. Previous positions: Biotechnology and Biological Sciences, Director (Ferrer); R&D Director & Member of the Board (Salvat); Associate Director of Discovery (Almirall); Associate Professor Cell Biology (UAB); Head of Pharmacology (Almirall). Direct executive and scientific responsibilities on teams successfully developing and launching: 5 New Molecular Entities (EU/USA/ASIA); 1 New Therapeutic Entity in USA/EU and 1 New Molecular DX product in oncology in EU. Co-author of over 40 peer-review publications, 110 communications and lectures and co-inventor of 18 international patent applications. Director of two doctoral theses. Former Chairman of the Program Committee of the International Union of Pharmacology (IUPHAR). Former member of the Board of Directors of ASEBIO. Chairman of the Catalan Society of Medical Biotechnology. Expert Panel Member and Mentor in CaixaImpulse Programme. Member of the Scientific Advisory Board at BIONAND. Member of the Scientific Committee of multiple Congresses and Meetings. Member of the Jury of various Scientific Awards. Frequent Invited Speaker at many Scientific or Academic events. Current interests: Open innovation & Collaborative Bio-Research. Advanced Therapies. Neuropharmacology. Ophthalmology. Molecular diagnostics. Research policies & sustainability.

Speakers:



"Oligonucleotide-based therapies. Development of RNAi compounds for the treatment of ocular conditions"

Ana Isabel Jiménez
COO, R&D Director
Sylentis (Spain)

Ana Isabel Jimenez obtained her Ph.D. in Biological Sciences from the Complutense University and MS in Biological Sciences (Spec. Biochemistry) from the Complutense University. She also obtained a Management Development Program diploma from the EOI Business School in Madrid. She completed post-doctoral training at the Department of Molecular Pathology National Cancer Research Center (CNIO) where she was author of several publications of international relevance. In 2003, she joined Genomic SAU (Zeltia group) in the position of Senior Researcher in R&D Department. In 2006, she was appointed Director of Research & Development at Sylentis (Zeltia group). She was promoted to her current position Chief Operations Officer at Sylentis (Pharmamar group) in 2013 where she is direct executive and scientific responsibilities on teams successfully developing drugs based on RNA interference for different pathologies. Co-author of over 20 peer-review publications, 50 communications and lectures, co-inventor of 16 international patent applications and more than 15 funded research programs. Mentor in the Mentoring program USC (Santiago Compostela University). Lecturer in postgraduate programs in the field of health in CESIF, Carlos III University, CEU, Aliter and IUCT. Lecturer in Biotechnology degree in Francisco de Vitoria University. Current interests: R&D. Oligonucleotides. RNA Interference. Drug development. Preclinical Models. Nanotecnology. Bio-informatics. Open innovation. Ophthalmology. Rare Diseases. Molecular Biology. Intellectual Property.




"New perspectives in retinal degenerative diseases"

José Carlos Pastor
Director
IOBA - Valladolid Cell Therapies (Spain)

MD (University of Navarra, Pamplona, 1974); PhD (university of Navarra, Pamplona, 1975). Specialist in Ophthalmology (University of Zaragoza, 1976). Full professor of Ophthalmology (University of Santiago de Compostela, 1979); Chairman of Ophthalmology (University of Valladolid, 1981). Founder of the IOBA (Eye Institute, University of Valladolid, 1994). Vice-Chancellor of Research (1987-1991, University of Valladolid). Current position: Full professor of Ophthalmology (University of Valladolid) and Chairman of Ophthalmology (Hospital Clinico Universitario, Valladolid), Director of the Retina Group at IOBA (Recognized Research Group by the University of Valladolid and Consolidated Research Unit by the Regional Government). General Coordinator of Oftared (Cooperative Research Network, Carlos III Institute of Health). Co-inventor of 8 patent applications. Author of 259 publications (120 in indexed journals), more than 500 communications and 32 books or chapters. Director of 43 doctoral thesis. Six stretches of research (six-year period) recognized by the Ministry of Science. Member of the Editorial Board of 12 scientific journals. Editor in Chief of the Spanish Journal of Ophthalmology (1995-2000), during that time journal was indexed and included in PubMed. Reviewer of 16 scientific journals. Member of the Biomedical Sciences Advisory Committee of the National Commission to Evaluate the Research Activity (2004-2006). 33 national and internationals awards (among them the Regional Annual Medal in Scientific and Technical Research and Innovation, Junta de Castilla y Leon, 2016). Reviewer of research projects for several National and International Agencies (FP7, Cordis EX2006C170303, of the European Union in the area of Health, Argentinian Ministry of Science). National expert of the CTN91 Committee of ISO standards (2018). Founder and Scientific Director of Vision R&D (first spin-off of the University of Valladolid). Lines of Research: Diabetic retinopathy, retinal detachment, vitreous substitutes, cell therapy for retinal diseases. Patron of the RetinaPlus Foundation, Spanish Ophthalmological Society Foundation and Jimenez-Arellano (University of Valladolid) Foundation.
 


"GPCR-based therapies. GLP-1 in diabetic retinopathy"

Rafael Simó
Head of the Endocrinology and Nutrition Service
VHIR - Hospital Vall d'Hebron (Spain)

Dr. Rafael Simó is the Director of Diabetes and Metabolism Research Unit at Vall d’Hebron Research Institute (VHIR), Head of the Endocrinology Department at Vall d’Hebron University Hospital, and Professor of Medicine & Endocrinology at the Autonomous University of Barcelona. His group belongs to CIBERDEM (the Spanish network for the research of diabetes and associated metabolic diseases). Prof. Simó has authored over 200 articles related to diabetes which have been published in high-profile peer-reviewed journals, besides 12 book chapters. He has participated in 22 research projects related to diabetic retinopathy and in 28 projects related to clinical diabetes. Prof. Simó is the Coordinator of the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (HEALTH-2011-FP7-278040). This consortium (constituted by 19 partners all of them leaders in diabetic retinopathy from 8 different countries) was funded by the EC for developing the first clinical trial using neuroprotective agents topically administered to prevent or arrest the development of diabetic retinopathy. In addition, Prof. Simó is the Diabetologist of Expert Committee on Diabetic Retinopathy and Vascular Diseases of the EVICR.net (European Vision Clinical Research). Prof. Simó is President of the European Association for the Study of Diabetes-Eye complications (EASD-ec), and renowned worldwide for his contributions to the pathophysiology of diabetic complications, in particular diabetic retinopathy. Prof. Simó received the Spanish Society of Diabetes Award (Rodríguez Miñón Award-2008) for a career in the field of Clinical Research in Diabetes, the “Dr. Josep Trueta” Award of the Academy of Medical Sciences from Catalonia (2011) for his innovative contributions in Biomedicine, and the Award of the Spanish Society of Endocrinology (2015) for the development and consolidation of a high-quality research group.

Animal Health
17:15 - 18:00
Animal Health
17:15 - 18:00

Chairperson:

Belén Barreiro
General Manager
Ingenasa (Spain)

Belen is a Veterinarian from the Universidad Complutense de Madrid and she has been involved during all her professional life in Biotechnological companies related with Animal Health, initially in Zeltia to move in 1994 to Ingenasa, company in which she currently holds the position of managing director. She actively participates in many professional associations being the vice president of Diagnostic for Animals and member of the board at Asebio and Avedila.

Speakers:



"Waiting for the “big one” alternative to antibiotics?"

Juan José Infante
CSO
ADL Bionatur Solutions (Spain)

Dr. Juan José Infante leads innovation and creation of new intelectual property as Chief Scientific Officer at ADL Bionatur Solutions. In the private biotech sector for the last 11 years, Dr. Infante has been mainly involved in development of biotechnological drugs for immune modulation and prevention of infectious diseases in animal health, one of the main strategic areas of ADL Bionatur Solutions.




Kym Anthony
Board Chairman and Interim CEO​
Avivagen (Canada) 

Mr. Anthony has extensive experience in capital markets, agriculture and life sciences. Mr. Anthony initiated and built Top Meadow Farms. At its height, the Top Meadow Group was the largest purebred breeder in Canada and the largest integrated “All-Natural” Beef program in Canada, with operations in Ontario and Saskatchewan. Mr. Anthony has received many awards for his contributions to agriculture from Canada and France.

Mr. Anthony serves as the Chairman of Top Meadow Investments and formerly served as Chairman and CEO of TD Securities and Vice-Chair of Toronto Dominion (TSX - TD), President and CEO of National Bank Financial (TSX- NA). Mr. Anthony also worked in Investment Banking and ran Fixed Income and Derivatives with CIBC/Wood Gundy (TSX- CM).




"Emerging Animal Health Opportunities under the umbrella of One Health"

Theo Kanellos
Director – Strategic Alliances
ZOETIS (Ireland)

Theo Kanellos qualified as a veterinarian from the Aristotle University of Thessalonica in Greece and has been awarded an MSc in microbiology and PhD in molecular medicine from the University of London. He also has a business diploma from the Ecole Supérieur de Commerce de Paris (ESCP). During his career he worked as a clinician, an academic, a governmental official and for the last fifteen years as part of the management within the Pharmaceutical Industry where he has held several strategic roles. He has managed research laboratories, business development transactions, scientific and multi-functional alliances teams and programmes in several organisations that have led to the spinoff of biotechnology companies, the award of significant scientific grants, the founding of major strategic partnerships and the registration and licensing of successful commercial products and services. In his current role in Zoetis he establishes business transactions and entrepreneurial partnerships with companies, VCs, universities, and governmental institutions, internationally.

   

Welcome Reception (Location TBD)
19:00 - 21:30
Welcome Reception (Location TBD)
19:00 - 21:30

FORO CAPITAL PYMES
Mediterraneo Room
FORO CAPITAL PYMES
Mediterraneo Room
Foro Capital PYMES - 8 excellent companies present to Foro Capital Pymes investors
11:00 - 14:00
Foro Capital PYMES - 8 excellent companies present to Foro Capital Pymes investors
11:00 - 14:00

Organised by :



Foro Capital Pymes, entity awarded by the European Commission as the best proposal in Europe for alternative financing for SME companies, will offer to 8 selected companies, the opportunity to present their investment proposals to the investment community, composed of Venture Capital, Family Office, Capital Risk, Corporate ...

Each company will have 10 minutes to present their investment proposal plus a round question of 5 minutes.

Companies that want to submit to investors in the forum, should download the executive summary form at www.forocapitalpymes.com and send it filled to be evaluated by the Selection Committee at empresas@forocapitalpymes.com.

Requirements:

  • Exclusive for Biotechnology companies and Health Sciences (biology, medicine, biomedicine, biochemistry and biodiversity)
  • Offer an acceptable profitability in the Medium Term.
  • Have a demonstrable route in technological development or research or with a turnover of around € 0.5M.
  • Be in search of between 0.5 and 10 M €.
  • Scalable projects with clear plans for growth and / or expansion.
 
About Foro Capital Pymes:

Foro Capital Pymes is an entity that organizes meetings between Spanish SMEs and investors. The most important national and international investors come to the forums (Family Office, Venture Capital, Venture Capital, corporate, etc.) and also financing entities.

In the 37 editions held in Madrid and Barcelona they have presented 274 companies and 535 investors have attended. Financing agreements are being closed in each of the forums held. To date, the entity has obtained funds of more than 25 million euros for participating companies.

Forum Promoters: MAB, Barcelona Stock Exchange, Madrid Stock Exchange, Keiretsu Forum, Enisa, Chambers of Barcelona and Madrid, Junta Andalucía, Caixa Fórum, ICF, Avalis, among others.

 

08:00 - 18:00 - REGISTRATION AND EXHIBITIONS OPENS

09:30 - 18:00 - PARTNERING ONE-TO-ONE MEETINGS

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
21:00
21:30
22:00
FINANCE & INVESTMENT PROGRAM
Italica Auditorium
FINANCE & INVESTMENT PROGRAM
Italica Auditorium
Going public: Is it the right time to consider international capital markets?
09:30 - 10:30
Going public: Is it the right time to consider international capital markets?
09:30 - 10:30

Sponsored by;




After receiving funding from venture capital & other type of private investors and having reached a level of maturity with outstanding clinical data, going public is the next step for many biotech companies, as it offers a platform for growth, greater liquidity and also more independence from private investors.

However, some questions are important to be considered.

  • When is the right time to take this step for a Spanish/European Biotech?
  • What requirements must the biotech company meet to access such funding?  Is this kind of funding appropriate for all companies?  Maturity in assets and management are key but is the bar moving upwards?
  • How important is the Market chosen to go public?
  • Are Dual Listings still alive? What is the tool box you would need for a dual-listing? EU only vs US-EU
  • How are Public markets to evolve in 2018?
  • What are going to be the most dynamic European markets in 2018?


  Chairperson:

 

Carlos Buesa
CEO
Oryzon Genomics (Spain)

He is a specialist in the Biotech Industry. Dr Buesa is BSc in Biology and got his PhD in Biochemistry (Molecular Biology) from the University of Barcelona, Spain in 1993. He was EU post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and later Senior Investigator at the Flemish Institute of Biotechnology (VIB). He has also taken the executive education programme (PADE) at the IESE Business School in Barcelona and several other additional educational programs in finances. In 2000, he founded Oryzon, where, since inception, he has served as CEO and Chairman of the Board. Under his leadership the company has got +50M € in several equity funding rounds +70 M € in non dilutive funds. After a transforming partnering deal of +$500 M with Roche in 2014, Dr Buesa leaded Oryzon to become a public company in 2015 in the Madrid Main Stock exchange. In March 2017 he leaded a successful 18.2M€ Pipes offering included institutional investors specialized in healthcare and life sciences from the US, Spain and rest of Europe reinforcing and diversifying the Company's shareholder base. The company has evolved from being a Genomics R&D oriented company in its early days to a clinical stage biopharma company highly specialized in epigenetics with a focus on Histone demethylases and particularly LSD1. Its two clinical programs, in Oncology and in CNS both being explored in a variety of Phase IIA trials and a third one on its way to start clinical studies, places today Oryzon at the forefront of the global Epigenetics space.

  Speakers:

 

Claudia D'Augusta
CFO
Tigenix (Belgium)

Before joining TiGenix in 2004, Claudia was finance director of Aquanima (Santander Group). Previous experiences include Deloitte & Touche in Milan and Apax Partners in Madrid. Claudia holds a degree in Economics and a Ph.D. in Business Administration at the University of Bocconi, Italy.

   


Susana de Antonio
Director, Spain Representative
EURONEXT (Spain)

Susana de Antonio joined Euronext in April 2017 as a Director and Spain Representative for Euronext, supporting Spanish Tech companies and their stakeholder in the Euronext IPO process but also in the pre- and post- listing phase. She has over 16 years’ experience in Venture Capital & Private Equity with 8 transactions completed and an aggregate value and equity invested of over €2.1bn and €330m respectively. She started her career at Netjuice Capital, an internet companies‘ incubator. After that she moved to the middle market Private Equity industry, spending 7 and 8 years respectively at Vista Capital (owned by Banco Santander) and L Capital (sponsorised by LVMH Group). She has been part of Pepe Jeans & Hackett and El Ganso Board of Directors. Susana holds a Bachelor Degree in Management and Finance Administration with majors in Finance and Accounting from CUNEF.

 

Jotin Marango
Managing Director
Roth Capital (U.S.A.)

Prior to Roth Capital, Jotin was an analyst with a number of investment banks, including H.C. Wainwright & Co., Collins Stewart, and Canaccord Genuity. His primary area of research focus are molecularly-targeted therapies in hematology, oncology, and autoimmune/inflammatory disorders. Previously, Jotin also served as Director of Acumen Bioventures, and COO of the Samuel Waxman Cancer Research Foundation, where he focused on new venture development in translational therapeutics. Jotin holds a Ph.D. in molecular biology and epigenetics, and an M.D. from the Mount Sinai School of Medicine in New York.

Academic Presentations
10:30 - 13:00
Academic Presentations
10:30 - 13:00

10:30 - TERTgent – Telomerase Gene Therapy Platform for short telomere-related diseases - CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

10:40 - IOT-Infrastructure for Omics Technologies (ICTS) - Centre Nacional d’Anàlisi Genòmica (CNAG-CRG)- Centre de Regulació Genòmica (Spain)

10:50 - Maimonides Institute for Biomedical Research of Córdoba - GOAT (Ghrelin-O-aciltransferase) - IMIBIC (Spain)

11:00 - Innovative therapy for the treatment of degenerative osteoarthritis (OA) - FIBICO(Spain)

11:10 - CloudMC - University Hospital Virgen Macarena/ FISEVI (Spain)

11:20 - Topical diltiazem for ischemic skin ulcers - Dermatology Department University Hospital Virgen del Rocío (Spain)

11:30 - Open Retinoscope - San Juan de Dios del Aljarafe Hospital/ FISEVI (Spain)

11:40 - Culture Medium and enrichment method and maintenance of cancer stem cells (CSCs) - FIBAO: Western Andalusian Biomedical Public Reserach Foundation/ibs.GRANADA: Granada Biomedical Research Institute (Spain)

11:50 - @ctivehip: Tele-rehabilitation platform to recuperate functional independency after suffering a hip fracture - FIBAO: Western Andalusian Biomedical Public Reserach Foundation/ibs.GRANADA: Granada Biomedical Research Institute

12:00 - Circulating epithelial cells isolation in peripheral blood - FIBAO: Western Andalusian Biomedical Public Reserach Foundation/ibs.GRANADA: Granada Biomedical Research Institute (Spain)

12:10 - Cell therapy for urinary incontinence - Institute of Biomedical Research in Malaga (IBIMA) (Spain)

12:20 - Dendrimeric antigens for drug allergy diagnosis - Institute of Biomedical Research in Malaga (IBIMA) (Spain)

12:30 - iSOL: Recombinant protein for the diagnosis and treatment of multiple sclerosis - Institute of Biomedical Research in Malaga (IBIMA) (Spain)

12:40 - Novel conjugation of oleic acid with an amphetamine derivative for prevention and treatment of steatohepatitis - Institute of Biomedical Research in Malaga (IBIMA) (Spain)

12:50 - FUNIN (Costa Rica)

Lunch Break
13:00 - 14:00
Lunch Break
13:00 - 14:00

Plenary Session - Philippe Monteyne. Partner, Fund+ (Belgium)
14:30 - 15:00
Plenary Session - Philippe Monteyne. Partner, Fund+ (Belgium)

Philippe Monteyne
Partner, Fund+ (Belgium)



Dr. Philippe Monteyne MD, PhD is a Partner at the VC Fund+ in Belgium. Fund+ is an open ended Fund for long term equity investments in innovative life sciences companies with a focus on Belgium. The fund wants to create sustainable shareholders’ value, contribute to the development of a leadership position of the Life Sciences sector and generate a tangible, beneficial societal impact.

Dr. Monteyne has held senior positions in SmithKline Beecham, GSK, and Sanofi. He served as the Head of Global Vaccine Development at GSK for several years, and then served as Senior VP-Head of Development and CMO at GSK Rare Diseases from 2010 to 2012.

​ More recently, he served as Vice President R&D France at Sanofi until early 2015. During that period, he was also Board Member of SARD (Sanofi Aventis R&D), of the LEEM (Pharmaceutical association in France "Les Entreprises du Médicament"​), of the Technological Research Institute (IRT) Bioaster in Lyon, and of the « Fondation Plan Alzheimer France ».

He is a Board Director of different Biotech companies, in Belgium, France and Spain. Dr. Monteyne was also visiting Professor of Neurology at the UCL (Université Catholique de Louvain), Brussels. He holds an M.D. degree and Ph.D. in Viral Immunology, both at the UCL, is a fully trained Neurologist, and has also been trained in Neuro-Immunology at Pasteur Institute in Paris.

Success stories in the Spanish biotech industry
15:00 - 16:00
Success stories in the Spanish biotech industry
15:00 - 16:00

Sponsored by;



During the past 10 years the Spanish Biotech sector has experienced an important transformation, evolving from research into an industry with a significant number of companies created. Some of these companies, originally funded by Spanish investors and public funds, have also managed to attract specialized international investors in the last few years.

Worth mentioning that the sector attracted close to 150M€ in 2017, with 68M€ invested directly by specialized international investors.

Some of these companies have been able to reach the market and to complete the cycle for their investors after being acquired by large multinational players.

In this session we will discuss about the main drivers of this evolution and what has been done right or wrong. Some of these outstanding companies will be presented and we will discuss with international investors which aspects still need to be improved to consolidate a sector that has a significant growth potential.

  Chairperson:

 

Paula Olazabal
Portfolio Director
Ysios Capital (Spain)

Paula monitors Ysios’ portfolio companies, being in charge of the reporting to the Funds’ investors. She is also in charge of evaluating investment opportunities from a financial and legal perspective. She serves on the board of Babyscripts and board observer at Dermalumics

Paula joined Ysios in 2008. From 2006 to 2008, she worked as associate at Sabadell Corporate Finance. Previously, she worked as an analyst at Nmás1 corporate finance (now Alantra). Throughout her career she has been involved in several buy and sell processes of companies in different sectors, having been involved in several valuations and financial restructurings.

  Speakers:

 

Accelerating Innovation Across Europe

Jeanne Bolger
Vice President
Johnson & Johnson Development Corporation (UK)

Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD).

 


What does it take to impact Life Sciences?

Philippe Monteyne
Partner
Fund + (Belgium)

Dr. Philippe Monteyne MD, PhD is a Partner at the VC Fund+ in Belgium. Fund+ is an open ended Fund for long term equity investments in innovative life sciences companies with a focus on Belgium. The fund wants to create sustainable shareholders’ value, contribute to the development of a leadership position of the Life Sciences sector and generate a tangible, beneficial societal impact.

He is a Board Director of different Biotech companies, in Belgium, France and Spain. ​

 


Sanifit, the leading anti-calcification company 

Joan Perello
CEO
Sanifit (Spain)

Joan is CEO and co-founder of Sanifit. He has led several financing rounds at Sanifit totalling >€40m. He served as Chief Scientific Officer at Sanifit from 2004 to 2013, and pioneered the international development of Sanifit’s lead candidate, SNF472, from academia to its clinical evaluation in patients suffering from calciphylaxis and ESRD. He is also board member at Numat Medtech and CIRCE Crystal Engineering. Joan is President of the Balearic Cluster of Biotechnology and Biomedicine. He is co-author of over 50 peer-reviewed international publications and co-inventor of 9 international patents.

 


Financing ahead or after a key value inflection milestone?

Claudia D'Augusta
Managing Manager
Tigenix (Spain/Belgium)

Before joining TiGenix in 2004, Claudia was finance director of Aquanima (Santander Group). Previous experiences include Deloitte & Touche in Milan and Apax Partners in Madrid. Claudia holds a degree in Economics and a Ph.D. in Business Administration at the University of Bocconi, Italy.

 

QIAStat-Dx 

Rafael Bru
Director of Instrumentation & Co-founder
STATdx (Spain)

Rafael Bru is systems engineer and co-founder of STAT-Dx, company which has recently been acquired by Qiagen. R. Bru worked during the last 7 years as Director of Instrumentation in the development of the QIAStat-Dx platform, an integrated IVD system for syndromic testing allowing to deliver efficient and timely patient-centered care based on multiplex molecular diagnostics.


Start-up presentations
16:00 - 18:00
Start-up presentations
16:00 - 18:00

16:00 - Dobecure (Spain)

16:10 - Innoup Farma (Spain)

16:20 - Remab (Spain)

16:30 - KalGene Pharmaceuticals Inc (Canada)

16:40 - Leadartis (Spain)

16:50 - Microviable (Spain)

17:00 - Molomics (Spain)

17:10 - Nanoligent (Spain)

17:20 - Iproteos (Spain)

17:30 - Bio Optical Detection (Spain)

17:40 - Talemnology (Spain)

17:50 - EpiDisease (Spain)

Evening networking event: Tapas route downtown Seville
20:00 - 22:00
Evening networking event: Tapas route downtown Seville
20:00 - 22:00

BREAKOUT SESSIONS
​Ronda Room
BREAKOUT SESSIONS
​Ronda Room
Drug Discovery - Farma Biotech Forum: From Research to the Pharmaceutical Market: Performance Systems and Pulling Factors
09:00 - 12:00
Drug Discovery - Farma Biotech Forum: From Research to the Pharmaceutical Market: Performance Systems and Pulling Factors
09:00 - 12:00

Sponsored by:



This session, organised by Farmaindustria under Spanish Technological Platform on Innovative Medicines and the ASEBIO Drug Discovery Group, aims to debate some of the most common barriers that have traditionally determined Spain’s limited scientific and technology capacity to transfer efficient results to industry and access to the market.

In this workshop the following topics will be addressed:​

  • Examples of good practice in certain instruments which are already working properly in Spain amongst other emerging instruments.
  • Recorded measures for operational selected instruments. Should a better output of current means be expected? What is hindering better outcomes obtained from the instruments mentioned?
  • What observable shortages can be identified? Is it possible that some instruments turn out to be inefficient or redundant?
  • Main gaps within collaboration processes between pharmaceutical industry and biomedical research in Spain. What can be done to obtain higher practical interaction in certain projects?
  • Is a positive outcome expected for Spanish biomedical research in terms of commercial application? When? What does it depend upon?

The session will be broken down into two different panels, each of them lasting 90 minutes. Each speaker will present some of the topics addressed (for 10 minutes), from their own perspective and professional experience. Afterwards, there will be an open discussion for 30 minutes.

Panel 1: PERFORMANCE SYSTEMS

In Spain, there are currently over 500 active biomedical research projects which could be potential candidates for transfer agreements towards the industry and access to the market. Still, most of them cannot find appropriate instruments of funding for their needs (technical, human or financial). In addition, there is frequently a lack of motivation and sensitivity towards the impulse and practical orientation of these projects. Are there enough transfer instruments ready to promote and boost project control and planning, flexible management, competitive leadership, entrepreneurial spirit and networking?. Which are they? Where are they? Are they the most appropriate ones? Do they have enough human and financial resources? Would new or different instruments be necessary?

PANEL OF PARTICIPANTS:

Chairwoman:



Amelia Martin
Responsible Spanish Technological Platform of Innovative Medicines
​Farmaindustria (Spain)

Amelia is PHD in Law. She joined FARMAINDUSTRIA in 2006 to manage the Spanish Technological Platform for Innovative Medicines, as Innovative Medicines Initiative mirror. She also is in charge of the coordination of different Biomedicine Project such as: BEST Project, as a strategic initiative promoted by the pharmaceutical industry with the aim of integrating all stakeholders, both public and private, to create an excellence based platform for clinical research in Spain. Amelia is member of the Data Protection Working Group of EFPIA. She participates, as key note speaker, in numerous international and national Congresses, Seminars and Events in relation with the promotion of Biomedicine in Spain.

  Speakers:

"Research networks as efficient transfer mechanisms. Current capability and growth expectations".

Carlos Diéguez
CIMUS & CIBERON Director
University of Santiago de Compostela (Spain)

 


"Traslation of Biochemical Research from the Academy: where do we stand?"

Manuel Fresno
Professor of Microbiology
Center of Molecular Biology - UAM (Autonomous University of Madrid)(Spain)

Dr. Manuel Fresno (1952) is now Full Professor of Microbiology and Head of the Inflammatory Disease research group at the Centro de Biologia Molecular of The Universidad Autonoma de Madrid and The Spanish National Research Council (CSIC). He was the former Director, for 4 years of this Center, which includes over 800 persons enrolled in more than 70 research groups at 5 Departments. He has been also Director of the Institute of Biologia Molecular and Chairman of the Department of Biologia Molecular of the UAM and since 2010 is Founding Member and Scientific Director of Diomune, a SME Pharma Biotech. After obtaining his PD.D in Biochemistry in Biochemistry in 1977 at the University Autonoma de Madrid, he moved to the United Sates in which he was Assistant Professor at Department of Pathology at Harvard University, Boston.

His initial PhD work on protein synthesis and ribosomal activity lead to the discovery of new antibiotics. Later at Harvard Medical School he contributed to the characterization of T lymphocyte subpopulations. He also studied the pathogenesis in Chagas disease. Recently, his main contributions are related to the regulation and role of Prostaglandins and cyclooxygenase 2 in several inflammatory diseases. His studies on innate immunity inflammatory receptors lead were the basis of the Foundation of the Spin-off Diomune.

 


"Are there any appropiate instruments? What do they need to be more effective?"

Francisca Vicente
Area Head of Screening and Target Validation
Fundación Medina (Spain)Health Institute Carlos III - ISCIII (Spain)




"What is required to draw the attention of the right investors?"

Miguel Vega
General Manager
Allinky BioPharma (Spain) 

Miguel Vega is General Manager at Allinky Biopharma since 2011, Allinky Biopharma is a biotech company fully devoted to drug discovery and development. From 2003 to 2011, Miguel served as the Director of Studies & Innovation, and Head of Technology Transfer, at the Spanish National Foundation for Genomics and Biotechnology (Genoma España). During this period he participated actively and co-led of one of the largest Public Biotechnology Seed Capital Funds in Spain. Before 2003, Miguel held different positions as: Director for Entrepreneurship and Business Development at the Madrid Science Park; Head of the Biotechnology Innovation Program at the Madrid Regional Platform for Science and Technology; and Scientific Agent at the Institute for Prospective Technological Studies (IPTS) of the European Commission. Miguel holds a Masters Degree in Agrofood Engineering from the Universidad Politécnica de Madrid and a Diploma from the Program for General Management (PDD) run by the IESE Business School.



What does a biomedical research project in Spain need to overtake the "Death Valley" of basic research and reach clinical research?


Alfonso Beltran
Deputy Director General for International Research Programmes
Health Institute Carlos III - ISCIII (Spain)

 
“Some figures on biomedical research transfer, in Spain and internationally - reasons for the differences”


Raúl Martin-Ruiz
Principal
Ysios Capital (Spain)

 
Panel 2: PHARMACEUTICAL INDUSTRY “PULLING” EFFECT


Several Public-Private Partnerships (PPP) programs, both at individual company level and public institution level, are beginning to play a significant role towards the transference of preliminary research outcomes from universities, hospitals, biomedical research centers and small biotech companies to pharmaceutical industry, thus becoming an essential component in preclinical and clinical phases. Which are they? How do they work? What are their growth perspectives?


PANEL OF PARTICIPANTS:

Chairman:




Javier Urzay
Deputy General Manager
Farmaindustria (Spain)


Economist from the Universidad Autónoma of Madrid and MBA from the Instituto Adriano Olivetti of Ancona (Italy), has worked as enterprise strategic consultant in DBK (Databank Group) and has been General Subdirector of Technological Services and Technology Transfer in the Centro para el Desarrollo Tecnológico Industrial (CDTI), I+D promotion agency of the Ministry of Industry, Tourism and Commerce, until 2001, date when he entered FARMAINDUSTRIA as Director of Coordination, Studies and Associate Service. Nowadays he holds the position of General Subdirector of FARMAINDUSTRIA, working primary in economical, strategic and research tasks, as well as general tasks of coordination department . Javier Urzay coordinates the industry representation in the Plataforma Tecnológica Española de Medicamentos Innovadores.

Speakers:

"There is a well known situation diagnosis but there are still effective means missing for results transfer. Why? Some ideas".

Andrés Fernández
Deputy Director General for International Research Programmes
Ferrer International (Spain)

PhD (Pharmacology; Univ. Barcelona) and MS (Pharmacy Spec. Biochemistry; Univ. Barcelona). Current position: Director of Ferrer Advanced Biotherapeutics at Ferrer. Previous positions: Biotechnology and Biological Sciences, Director (Ferrer); R&D Director & Member of the Board (Salvat); Associate Director of Discovery (Almirall); Associate Professor Cell Biology (UAB); Head of Pharmacology (Almirall). Direct executive and scientific responsibilities on teams successfully developing and launching: 5 New Molecular Entities (EU/USA/ASIA); 1 New Therapeutic Entity in USA/EU and 1 New Molecular DX product in oncology in EU. Co-author of over 40 peer-review publications, 110 communications and lectures and co-inventor of 18 international patent applications. Director of two doctoral theses. Former Chairman of the Program Committee of the International Union of Pharmacology (IUPHAR). Former member of the Board of Directors of ASEBIO. Chairman of the Catalan Society of Medical Biotechnology. Expert Panel Member and Mentor in CaixaImpulse Programme. Member of the Scientific Advisory Board at BIONAND. Member of the Scientific Committee of multiple Congresses and Meetings. Member of the Jury of various Scientific Awards. Frequent Invited Speaker at many Scientific or Academic events. Current interests: Open innovation & Collaborative Bio-Research. Advanced Therapies. Neuropharmacology. Ophthalmology. Molecular diagnostics. Research policies & sustainability.


"Open Innovation from Big Pharma: the J&J approach"


Antonio Gomez
New Ventures Lead Spain
Johnson & Johnson Innovation (Spain)




“Innovation strategies and creation of scientific networks”.

Maria Ángeles Martínez-Grau
Senior Research Advisor
Eli Lilly & Co. (Spain)

Maria Angeles received her doctorate in Organic Chemistry from Universidad Complutense in 1994 and the “National Award for Young Investigators” (RSEQ) in 1995. After two years of postdoctoral research at the University of Pittsburgh, she became Associate Professor at Universidad Complutense. Maria Angeles joined Lilly in 1998 at the Spanish site and accepted an assignment for three years in Indianapolis. As medicinal chemist, she has contributed to deliver 12 clinical candidates in the areas of Neuroscience, Obesity and Diabetes. In 2017, she accepted the role of Coordinator of External Innovation in Europe in addition to her scientific responsibilities.


"Preclinical research collaborations in the pharmaceutical industry: incentives and barriers".


Arsenio Nueda-Marin
Head, Molecular Biology
Department of Biology, Almirall (Spain)



“Diseases of the Developing World. Open Lab’s experience in Spain”

Jose Fiandor
Director - Kinetoplastids Unit
GlaxoSmithKline (Spain)





"From Academic Ideas to Industrial Application - Max Planck's Lead Discovery Center  as a Model for a Translational Incubator".

Peter Nussbaumer
Managing Director & Head of Medicinal Chemistry
Lead Discovery Center GmbH (Germany)


Dr. Peter Nussbaumer has more than 30 years of industry experience in drug discovery and early drug development. Currently, he is Managing Director and Head of Medicinal Chemistry at the Lead Discovery Center GmbH (LDC) in Dortmund, Germany. In this function Peter has been co-responsible for building-up and running this unique translational drug discovery organisation founded by the Max Planck Society, working at the interface of academia and industry. He is member of several international scientific advisory boards and serves as advisor to private and public funding bodies. Peter is (co)author of >30 patent applications and >80 peer-reviewed publications and referee to various journals.

Before joining LDC, Peter was Executive Director at the Novartis Institutes for BioMedical Research in Vienna, Austria, heading the Chemistry Department. Peter has a Dr. degree from the Vienna University of Technology, Austria.  

The Spanish Technological Platform for Innovative Medicines has financial support from the Ministry of Science, Innovation and Universities



 

Clinical Trials
12:00 - 13:00
Clinical Trials
12:00 - 13:00

Sponsored by;

 

Chairperson:

 

“Bioanalysis of Therapeutic Proteins: Pharmacokinetics and Immunogenicity”

CarlesCelma Lezcano
Biologics Scientific Director
Kymos Pharma Services (Spain)

Ph. D. in Chemistry .  University of Barcelona:  Six years as Head of the Mass Spectrometry Facility of the Chemistry Faculty of the University of Barcelona. More than 20 years in R &D at Ipsen as Head Mass spectrometry and Bioanalysis Director, managing the Departments of Mass Spectrometry and Immunology. Since 2012  Scientific Director of Biologics at Kymos Pharma Services S.L. supervising scientifically and technically  the departments of Biopharmaceutical  testing and Immunology. Experience: Peptide synthesis. Application of several LC-MS/MS techniques and Immunological methods (RIA, ELISA, ECLA )  to the structural characterization and bioanalysis  of small molecules, peptides, proteins and glycosaminoglycans.  Immunogenicity studies. Development and validation  of methods and sample analysis  for preclinical and clinical studies under GMP and GLP.  15 publication in different international scientific journals and more than 40 communications to national and international congresses.


Speakers:



"The BEST Project: fostering Clinical Trials in Spain"

Amelia Martín
Responsible of the Spanish Technological Platform for Innovative Medicines
Farmaindustria (Spain)

Amelia is PHD  in Law. She joined FARMAINDUSTRIA in 2006 to manage the Spanish Technological Platform for Innovative Medicines, as Innovative Medicines Initiative mirror. She also is in charge of the coordination of different Biomedicine Project such as: BEST Project, as a strategic initiative promoted by the pharmaceutical industry with the aim of integrating all stakeholders, both public and private, to create an excellence based platform for clinical research in Spain. Amelia is member of the Data Protection Working Group of EFPIA. She participates, as key note speaker, in numerous international and national Congresses, Seminars and Events in relation with the promotion of Biomedicine in Spain.




César Hernández
Head of Department, Department of Medicines for Human Use
Spanish Agency of Medicines and Medical Devices (Spain)

Dr. César Hernández MD, PhD. joined the Spanish Agency for Medicines and Medical Devices as a Head of the Human Medicines Department in 2009.  Prior, he was the deputy Medical Director of the Hospital Clínico San Carlos in Madrid for three years and worked as rheumatologist at the same Hospital  for 16  years.  He graduated from medicine and surgery, specialist in Rheumatology in 1987 at the Complutense University of Madrid and received his PhD in 1996 at the same university.




“The Canadian Advantage in Clinical Trials”

Vatché Bartekian
Chairman
Clinical Research Association of Canada (Canada)

Mr. Bartekian is President and Founder of Vantage BioTrials, a privately-held Canadian Contract Research Organization specialized in clinical trial management services. He's contributed his strong drug development knowledge to the pharma and clinical research industry for over 20 years and has gained vast experience handling complicated trials across an array of therapeutic areas. He's an expert in Clinical Operations, Project Management, Quality Assurance and Clinical Monitoring.  Mr. Bartekian is also the Chairperson of the Clinical Research Association of Canada, a non-profit peer-to-peer networking and educational group based out of Toronto. He is an avid public speaker and organizer of the Canada Talks Pharma conference series, which attracts ~300 life science professionals to Canada on an annual basis to discuss challenges and solutions for clinical trials.  Mr. Bartekian was recently honored with an appointment as an Advisor to Global Affairs Canada's Life Science group and regularly provides the Canadian Government with his advice on the future of the clinical trial landscape in this country in order to better position Canada as an effective and competitive place to run clinical studies.  He has also been nominated for EY’s 2015 “Entrepreneur of the Year” award in Life Sciences and has been named as “Emerging Pharma Leader” by PharmaExecutive Magazine in 2011 for his novel approach to managing clinical studies in the era of lean operations.




“Next Generation Clinical Trials, how Data Science can Fast-Forward Clinical Development”

Sadiq Lula
Associate Director, Analytics Center of Excellence, R&D Solutions
IQVIA (Spain)

o Sadiq Lula BSc in Pharmaceutical and Chemical Sciences, Liverpool John Moores University. Sadiq has 14+ years of experience in research and analytics within the healthcare industry, spanning academia, clinical research, public health, patient advocacy and pharmaceutical R&D. Sadiq has been a key contributor in the development of clinical trials, interventional and population-based studies, and Real World Data analyses at Pfizer, the Medical Research Council, University of Cambridge, Robert Gordon University and IQVIA. Sadiq was previously a researcher at the MRC, University of Cambridge, a visiting Senior Research Fellow at Robert Gordon University and a member of the Readership Panel at Poole Hospital NHS Foundation Trust. Sadiq has published 17 articles and contributed to another 7 articles in peer reviewed scientific journals and 20+ publications at international conferences.

Lunch Break
13:00 - 14:00
Lunch Break
13:00 - 14:00

Plenary Session - Philippe Monteyne. Partner, Fund+ (Belgium)
14:30 - 15:00
Plenary Session - Philippe Monteyne. Partner, Fund+ (Belgium)

Philippe Monteyne
Partner, Fund+ (Belgium)



Dr. Philippe Monteyne MD, PhD is a Partner at the VC Fund+ in Belgium. Fund+ is an open ended Fund for long term equity investments in innovative life sciences companies with a focus on Belgium. The fund wants to create sustainable shareholders’ value, contribute to the development of a leadership position of the Life Sciences sector and generate a tangible, beneficial societal impact.

Dr. Monteyne has held senior positions in SmithKline Beecham, GSK, and Sanofi. He served as the Head of Global Vaccine Development at GSK for several years, and then served as Senior VP-Head of Development and CMO at GSK Rare Diseases from 2010 to 2012.

​ More recently, he served as Vice President R&D France at Sanofi until early 2015. During that period, he was also Board Member of SARD (Sanofi Aventis R&D), of the LEEM (Pharmaceutical association in France "Les Entreprises du Médicament"​), of the Technological Research Institute (IRT) Bioaster in Lyon, and of the « Fondation Plan Alzheimer France ».

He is a Board Director of different Biotech companies, in Belgium, France and Spain. Dr. Monteyne was also visiting Professor of Neurology at the UCL (Université Catholique de Louvain), Brussels. He holds an M.D. degree and Ph.D. in Viral Immunology, both at the UCL, is a fully trained Neurologist, and has also been trained in Neuro-Immunology at Pasteur Institute in Paris.

Gene editing
15:00 - 16:00
Gene editing
15:00 - 16:00

Sponsored by:



For a long time, researchers have pursued a means of efficiently manipulating DNA. The diversity, modularity, and efficacy of CRISPR has made genome editing much easier and faster than ever before rapidly becoming an indispensable tool for biological research. This technology provides important scientific opportunities for curing genetic diseases and engineering desirable genetic traits, as well as new approaches to high-throughput functional genomic screens, drug screens and point-of-care diagnostics. CRISPR technology has generated excitement for new and improved gene therapies, whilst optimism must be kept in check, recent studies highlight its potential to make an impact on human disease. In the “Gene Editing” session the basic mechanisms of the CRISPR systems and their general applications will be reviewed.

Chairwoman & Speaker:



“CRISPR system: the future of genetic engineering and its applications”

Sandra Rodriguez-Perales
Head of Unit
Molecular Cytogenetics and Genome Editing Unit. Human Cancer Genetics Programme/ Spanish National Cancer Centre (CNIO), Madrid (Spain)

Sandra Rodriguez Perales is Head of the Molecular Cytogenetics and Genome Editing Core Unit at the Spanish National Cancer Centre (CNIO). In 2004 she obtained a PhD from the Complutense University of Madrid. Subsequently, she moved to the LMB-MRC in Cambridge (UK) to work in the generation of animal models of chromosomal translocations associated with neoplastic processes. She then joined the CNIC where she worked in the Department of Regenerative Medicine in the field of gene therapy and human stem cells. She has a broad background in Genetics and Molecular Cytogenetics, with specific training and expertise in Genome Engineering and generation of cancer related cellular models. Her research interest includes the study the role of acquired chromosomal abnormalities in cancer through: (1) the molecular characterization of genetic and cytogenetic markers, and (2) the design of human stem cell models carrying chromosome rearrangements.




“Gene Editing to cure hematopoietic inherited diseases. The Gene Therapy 2.0”

José Carlos Segovia
Head of Unit
CIEMAT (Spain)

Dr. José Carlos Segovia has focused his research on the study of hematopoietic stem cells (HSC), in their interaction with viral pathogens, in their purification and manipulation ex vivo and in the transfer and gene editing of HSC, to develop protocols of gene therapy for the treatment of genetic diseases with hematopoietic pathology. Doctor in Sciences from the Autonomous University of Madrid (1993) and currently Head of the Unit of Differentiation and Cytometry and of the Cell Cycle and Cell Separation Cytometry Laboratory, in the Basic Research Department of the Center for Energy, Environmental and Technological (CIEMAT).


“Genome editing permits reliable genotype-phenotype association studies and screening of targeted drugs”

Pablo Menéndez
Campus Research Director
Josep Carreras Foundation (Spain)

Immunotherapy
16:15 - 18:00
Immunotherapy
16:15 - 18:00

In collaboration with:



16: 15 – 17:00 Part 1 - Monoclonal antibodies:


Sponsored by:





Chairperson:



Luis de la Cruz-Merino
Clinical Oncology Department Head
Universitary Hospital Virgen Macarena Macarena (Spain)

Dr Luis de la Cruz-Merino is Head of Hospital Universitario Virgen Macarena Clinical Oncology Department since April 2017. He has authored and co-authored more than 50 publications in journals like NEJM, Lancet, Lancet Oncology, Annals of Oncology and others. His main area of research interest is immunotherapy of cancer, especially applied to melanoma, lymphoma and breast cancer.

Speakers:



Ignacio Javier Melero Bermejo
Co-Director of the Immunology & Immunotherapy Service
Center for Applied Medical Research (CIMA), Clínica Universidad de Navarra (Spain)

Dr. Melero started out in biomedical research as a resident of immunology at the prestigious department of this specialty in Hospital Universitario de la Princesa (Madrid). He completed his doctoral thesis with Professor Miguel López-Botet identifying and functionally studying natural killer cell receptors. His work obtained the Outstanding Doctorate Award. In 1994 he joined Bristol Myers Squibb Company as a researcher in cancer immunotherapy in his institute in Seattle (WA). The result of his three years of work in this environment are pioneering publications in the knowledge of costimulation of antitumor immune responses and the use of immunostimulatory monoclonal antibodies. During this period he worked with Professor Lieping Chen in the division led by Professor Karl E. Hellström. In 1998 he returned to Spain in the field of CIMA and Clínica Universidad de Navarra. In these centers he has led a multidisciplinary team working in cancer immunotherapy with cell therapy techniques, gene therapy and monoclonal antibodies. Dr. Melero is a professor of immunology at the University of Navarra, has directed 12 PhD thesis (7 of them obtained the Outstanding Doctorate Award), and has been principal researcher in over 20 clinical trials of immunotherapy (both sponsored by industry and by the center itself). His work has resulted in three patents transferred to industry.

 


“New trends in antibody-based immunotherapy”

Luis Alvarez-Vallina
Immunotherapy and Cell Engineering research group
Aarhus University (Denmark), Cancer Immunotherapy Unit (UNICA) Hospital Universitario 12 de Octubre, Madrid (Spain), Director Immunology University Chair Merck- Francisco de Vitoria University (Spain)

 
Khatereh Ahmadi
Executive Director
Oncology Search and Evaluation Lead. European Innovation Hub, MSD (UK)





“The BITEs contribution to the hematological patient”

Pere Barba Suñol
Hematology Department
Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona (Spain)

Pere Barba was born in Barcelona, Spain. He achieved his Medical Degree in the Autonomous University of Barcelona and did his fellowship in Hematology at Hospital Sant Pau of Barcelona. He obtained his clinical PhD at the Autonomous Univeristy of Barcelona with a thesis about liver complications in recipients of allogeneic hematopoietic cell transplantation. Dr. Barba completed his training in Bone Marrow Transplant in Hôpital Saint Louis in Paris, France and he served as Visiting Investigator at the Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York. Currently, he is a member of the Hematology Department of Hospital Vall Hebron in Barcelona and Associate Professor at the Autonomous University of Barcelona. Dr. Barba has published more than 60 articles in international peer reviewed journals and book chapters on Acute Lymphoblastic Leukemia and Bone Marrow Transplantation. He is an active member of the ALL-Spanish PETHEMA Group and the Acute Leukemia Working Party of the EBMT. He is currently leading a research program on virus-specific T-cells funded by the Spanish Government. His fields of interest include acute lymphoblastic leukemia, allogeneic hematopoietic cell transplantation, immunotherapy, cellular therapy and bioethics.



17 :00 – 18 :00 Part 2- CART-T cells 


Sponsored by:





Chairperson:


Inmaculada Herrera Arroyo
Director Cell Therapy Unit
Reina Sofia Universitary Hospital (Spain)

 
Speakers:




"Is it possible to develop an academic CART approach for treating patients in our hospitals?”

Manel Juan Otero
Head of Immunotherapy Section
Hospital Clínic de Barcelona (Spain)

Head of Immunotherapy Section. Immunology Service. Hospital Clínic de Barcelona. Director of Cell Immunotherapy. Hospital Sant Joan de Déu. 10 doctoral theses directed (4 co-directed). 105 publications highlighting 75 articles in journals with impact factor (global IF 487,321). 26 research projects with competitive grants. 3 Spanish patents with European extension.




"How to improve CAR T cells from the vector´s perspective”

Francisco Martín Molina
Director of the Gene and Cell Therapy Unit
Genyo, (Pfizer-University of Granada-Junta de Andalucía Center of Genomics & Oncology Research) (Spain)

Dr Martin is Team Leader of the Gene and Cell Therapy Group (GCT) at the Centre of Genomic and oncology (GENYO- Granada) and Funder and Scientific director of LentiStem Biotech, a Spinout focused on the development of SAFER AND MORE EFFICIENT gene delivery systems for gene-cell therapy applications. Dr Martin has over 25 years of experience in the gene therapy field, with special interest in lentiviral vectors development for applications to the genetic correction of rare disorders and to immunotherapy of cancer.


Franco Locatelli
Professor of Pediatrics
University of Pavia / Director, Department of Pediatric Hematology and Oncology IRCCS Ospedale, Pediatrico Bambino Gesù Piazza (Italy)

 
Enrique Granados
Director en Medical Affairs
Gilead Sciences (Spain)

 


"From Immunomodulation to cellular therapy”

Marta Durán Delmàs
Executive Medical Advisor Multiple Myeloma
Celgene (Spain)

With a degree in Medicine and Surgery and Specialist in Clinical Pharmacology, Marta holds a Master in Pharmacoepidemiology. She joined Celgene as regional scientific adviser, to become later in Executive Medical Advisor in Multiple Myeloma. Currently, Marta is Associate Director of Medical Affairs CAR-T of Celgene Spain and Portugal. Before starting his career in the industry, she worked as Associate Physician in Clinical Pharmacology at Vall d'Hebrón Hospital and as a teacher at the Faculty of Medicine of the AUB.

Evening networking event: Tapas route downtown Seville
20:00 - 22:00
Evening networking event: Tapas route downtown Seville
20:00 - 22:00

BREAKOUT SESSIONS
Bahia Room
BREAKOUT SESSIONS
Bahia Room
Industrial Biotechnology & Circular Economy Forum
09:00 - 12:00
Industrial Biotechnology & Circular Economy Forum
09:00 - 12:00

This session aims to address different perspectives about industrial biotechnology and circular economy trends. In a growing population context, a fair food supply, mitigation of climate change effects and dependency of fossil fuels must be tackled to ensure sustainability. Industrial biotechnology and circular economy have the potential to provide solutions for the main environmental, societal and economical challenges. For this purpose, science, research and innovation are key factors to set up the path towards a more efficient use of resources.

This workshop will be broken down as follows:
• Strategic public policies to support Circular Economy and Bioeconomy
• Success stories of private initiatives
• Projects contributing to boost Circular Economy and Industrial Biotechnology sectors

What is circular economy? Which are the detected barriers to implement circular business models? Which opportunities have been detected? How can industrial biotechnology contribute? Is circular economy profitable? These and many more issues will be discussed during this session.

Chairperson:

Manuel Lainez Andrés
Manager
Observatory of Bioeconomy (Spain)



Speakers:

STRATEGIC PUBLIC POLICIES:



“Andalusian Circular Bioeconomy Strategy”

Judith Anda
Coordinator of the Andalusia Bioeconomy Strategy
Andalusian Government (Spain)

Engineer on Agronomy (University of Cordoba). MBA & Rural Development. Master on Environmental Impact Evaluation. - Vice Minister’s Technical Counsellor. Mrs Judit Anda has held positions of High Responsibility (2005-2013) for the Regional Government of Andalusia. Coordination of Bioeconomy, Strategy, the project Model Demonstrator Region and the S3 Platform Agri-food on Traceability and Big Data at European level.


SUCCESS STORIES:

Iryna Sukhotska
Business Development Manager
Biopolis (Spain)




Andrés Pascual
Head of Environment, Bioenergy and Industrial Hygiene
AINIA (Spain)

Agriculture Engineering by the Universidad Politécnica de Valencia. 21 years experience working at ainia technology center in the area of technological innovation for the food, environment and bioenergy sectors . Main expertise on technologies enabling biocircular economy like anaerobic digestion of organic waste for biogas/biomethane production, biological wastewater treatment technologies and microalgae or lemna cultivation and use, and in the last years on biomass valorization through biorefinery models including bioenergy and bio based products like bioplatics, biomaterials or biobased chemicals.




“Battling Food Waste and Plastic Pollution with a Single Circular Solution "

Cait Murray-Green
CEO
CuanTec (UK)

Dr Cait Murray-Green CEO CuanTec, Scotland, UK. A researcher who has made a successful transition to business leader with experience from both the Biotech and Environmental sectors and has helped to found CuanTec, one of the Top 10 start-ups in Scotland which is taking on the challenges of food waste and plastic pollution by creating compostable bioplastic alternatives from chitin and chitosan sourced from the fisheries industry.




“Sabana Project an Example of Bioeconomy”

Joaquín Pozo
R& D Project Manager
Biorizon (Spain)

Dr. Joaquín Pozo Dengra has studied Chemisrtry at the University of Almería where he received his PhD in 2010 in the area of biochemistry and molecular biology. He has been working for 6 years as Head of Biotechnology area and Director of analytical services department at TECNOVA Center of Technology. He has a large experience in developing and managing several national and international Projects as principal investigator and project manager. He is partner and head of R&D projects in Biorizon Biotech. Co-supervisor of 3 Master thesis, he is author in 9 articles published in refereed journals, 1 chapter of book, 3 patents, more than 30 congress communications and 3 sequences submitted to GenBank. He is member of the editorial Board of the journals “Food and Raw Materials” and “Science Evolution”. He works as R&D consultant for a large number of national and multinational companies being the author of more than 30 projects funded.


EUROPEAN PROJECTS:

Reinwaste:
"Zero inorganic waste. Solutions for the Agri-Food Sector"
Mª Antonia Cobacho
Department of International Relations
Agency for the Management of Agriculture and Fisheries of Andalusia, Andalusian Government (Spain) 


ICT-Biochain:
"ICT Tools in Efficient Biomass Supply Chains for Sustainable Chemical Production"
Esperanza Perea
Vice Counseling Technical Counselor
CAPDER (Spain)


Agriforvalor:
“Agriforvalor: main achievements and highlights"
Cristina Cabeza
Agriforvalor project Responsible for Andalusia
Andalusian Agency of Knowledge (Spain) 


SuperBIO:
SUpport and PartnERship for the development of multiple sustainable and market ready value chains in the BIObased economy”
Gloria de la Viña
Andalusian Technological Corporation (Spain)


Biovoices and Biobridges:
“Biovoices and Biobridges projects”
Beatriz Palomo
Project Manager
Spanish Bioindustry Association-ASEBIO (Spain)


Urbofin:
“URBIOFIN Project in the CLAMBER R&D Biorefinery”
Javier Mena Sanz
Scientific Coordinator
CLAMBER R&D Biorefinery
Regional Institute for Research and Development of Agrifood and Forestry of Castilla-La Mancha – IRIAF (Spain)


Biorescue, Percal, Scalibur NextGenRoadFuels:
“Urban Biorefinery Platform towards a Circular Bioeconomy”
Goizeder Barberena
Biomass Strategy and Business Development Manager
National Renewable Energy Centre in Spain – CENER (Spain)
 
 

Artificial Intelligence: how your company can take advantage of it?
12:00 - 13:00
Artificial Intelligence: how your company can take advantage of it?
12:00 - 13:00

Sponsored by:



What is artificial intelligence (AI)? What does it mean for R&D and Pharma business? And how can you and your company take advantage of it?

In this session, we will answer these questions and challenge common misconceptions surrounding AI and how they can be harnessed to support the healthcare sector needs.

We will analyze examples of how the collective intelligence of people and computers together can solve business problems that not long ago were considered impossible.

Chairperson:



Carlos Galmarini
Head Cell Biology and Pharmacogenomics
Pharmamar (Spain)

Carlos M. Galmarini is the head of cell biology & pharmacogenomics department at PharmaMar, a spanish biotech/pharma public company devoted to the discovery and development of anticancer agents from marine source. With more than 25 years of experience in oncology, his research focus has covered anticancer drug discovery and development, pharmacogenomics, tumor microenvironment and tumor drug resistance.

He is currently leading the implementation and development of disruptive analytical methodologies to accelerate the drug discovery process and increase its odds of success by using artificial intelligence. Carlos M. Galmarini received his MD from the University of Buenos Aires (Argentina) and his PhD and HDR from the Université Claude Bernard Lyon 1 (France). He completed his training in medical oncology at the Hospital Municipal de Oncología “María Curie” in Buenos Aires, and also different fellowships in hematology/oncology at the City of Hope National Cancer Center in Los Angeles and the Centre León Bérard and Hôpital Lyon Sud in Lyon (France).

Speakers:



“Artificial Intelligence applied in Drug Discovery & Development: a dream or a reality?”

Ciriaco Maraschiello
Global Head Drug Development
Aptuit, an Evotec Company (Italy)

 


Brigham Hyde
CEO of Precision Health Intelligence & Partner
Symphony AI (USA)

Brigham Hyde, Ph.D., is the CEO of Precision Health Intelligence & Partner at Symphony AI. He was previously Chief Data Officer and SVP of Analytics at Decision Resources Group where he led client direct data analytics for Life Sciences. Brigham joined DRG as part of the acquisition of Relay Technology Management in January 2014. As CEO and co-founder of Relay Technology Management he developed proprietary analytics software and data aggregation tools. Dr. Hyde has over 15 years life science experience and prior to founding Relay Technology Management was an equity research analyst in Medical Technology and Life Science Tools at Cowen & Co. in Boston. Dr. Hyde received his Ph.D. in Clinical Pharmacology from the Tufts University School of Medicine, where he is currently an adjunct professor of Pharmacology and experimental therapeutics.

Lunch Break
13:00 - 14:00
Lunch Break
13:00 - 14:00

Plenary Session - Philippe Monteyne. Partner, Fund+ (Belgium)
14:30 - 15:00
Plenary Session - Philippe Monteyne. Partner, Fund+ (Belgium)

Philippe Monteyne
Partner, Fund+ (Belgium)



Dr. Philippe Monteyne MD, PhD is a Partner at the VC Fund+ in Belgium. Fund+ is an open ended Fund for long term equity investments in innovative life sciences companies with a focus on Belgium. The fund wants to create sustainable shareholders’ value, contribute to the development of a leadership position of the Life Sciences sector and generate a tangible, beneficial societal impact.

Dr. Monteyne has held senior positions in SmithKline Beecham, GSK, and Sanofi. He served as the Head of Global Vaccine Development at GSK for several years, and then served as Senior VP-Head of Development and CMO at GSK Rare Diseases from 2010 to 2012.

​ More recently, he served as Vice President R&D France at Sanofi until early 2015. During that period, he was also Board Member of SARD (Sanofi Aventis R&D), of the LEEM (Pharmaceutical association in France "Les Entreprises du Médicament"​), of the Technological Research Institute (IRT) Bioaster in Lyon, and of the « Fondation Plan Alzheimer France ».

He is a Board Director of different Biotech companies, in Belgium, France and Spain. Dr. Monteyne was also visiting Professor of Neurology at the UCL (Université Catholique de Louvain), Brussels. He holds an M.D. degree and Ph.D. in Viral Immunology, both at the UCL, is a fully trained Neurologist, and has also been trained in Neuro-Immunology at Pasteur Institute in Paris.

Market access - Part 1: Innovation and access to medicines in the Spanish Health Care System
15:00 - 16:00
Market access - Part 1: Innovation and access to medicines in the Spanish Health Care System
15:00 - 16:00

Sponsored by:



Part 1: "Innovation and access to medicines in the Spanish Health Care System"


Health expenditure in developed countries has been increasing in recent years and the upward pressure is expected to be maintained because of demographic factors such as continuous population growth, population ageing and increased rates of chronicity. Different administrations tend to put the focus on pharmaceutical expenditure as a measure of containment of total health expenditure. At the international level, the costs per molecule approved are increasing. It is necessary to analyze and enhance the institutional framework in which actors of the system operate so that innovation is encouraged and incentivized in such a way that patients have access to therapeutic innovations. The round table will also discuss the role of the different actors in securing an adequate incentive framework to foster innovation and access to new therapeutical options.

Chairperson:



Ana Polanco
Market Access & Government Affairs Director
Merck (Spain)
Health Council Delegate and Member of the Board of Directors
ASEBIO (Spain)

Ana Polanco is director of corporate Affairs at Merck since 2015.

From this position, she directs Pricing, Tenders, Economic Evaluation, Market Access, Institutional Relations and relations with Patient Associations at Merck.

Ana is part of the board of Directors of ASEBIO, and in this last association she is the delegate of the Health Commission and coordinator of the Market Access Group. She is also a member of the Merck Salud Foundation Board of Trustees.

Ana has a PhD in pharmacy from the University of Salamanca. She made the FIR in the specialty of clinical microbiology in the Hospital Ramón y Cajal (Madrid) and the doctorate in Pharmacy at the National Center of Microbiology (Madrid). In addition, she has a master in Marketing and business administration from the UNED and the Program of Public Agenda Power and Counterpower given by ESADE.

She started in the pharmaceutical industry in 1997 in Gilead Sciences, and has also worked at Bristol Myers Squibb and Novo Nordisk, before joining Merck Spain.

In the academic field, she is an external lecturer in the Masters of Market Access and Health Economics of public universities such as the Carlos III University of Madrid, the University of Salamanca and the San Pablo-CEU University and in private business schools such as EPHOS, Talento Farmacéutico and MPG.

Speakers:

Jorge Aboal
Health Care Director
Galician Health Service – SERGAS (Spain)


Begoña Barragán
President
Spanish Cancer Patients Group-GEPAC (Spain)

 

Market access - Part 2: New challenges and Access tools in the Spanish Healthcare System
16:00 - 17:00
Market access - Part 2: New challenges and Access tools in the Spanish Healthcare System
16:00 - 17:00

Sponsored by:







Speakers:

María Dolores Fernández Jimenéz
Head of Market Access and Policy
Amgen (Spain)


Ignacio Schoendorff
Director Market Access & Reimbursement
Gilead Sciences (Spain)

 


Juan José Polledo
Director de Governmental Affairs & Market Access
Celgene (Spain)

PhD in Veterinary and with a degree in Law, Juanjo has more than 30 years of experience in the Health sector. During his career, he has made multiple publications. Among his positions are also the General Directorate of Public Health of the Ministry of Health and Consumer Affairs from 1991 to 2000. He joined Celgene in 2016 as its Governmental Affairs & Market Access Director.

 

Antibiotic resistance
17:00 - 18:00
Antibiotic resistance
17:00 - 18:00

Sponsored by;

 

Chairperson:

“New paradigms to fight MDR organisms”

Domingo Gargallo-Viola
CSO
Abac Therapeutics (Spain)

PhD in Sciences from University of Barcelona. Management Development Program from IE Business School, and IESE Business School. Over 30 years of experience in the pharmaceutical industry. Currently CSO at ABAC Therapeutics, a company focused on the discovery of first-in-class, pathogen-specific, narrow spectrum antibiotics with novel mechanism of action for the treatment of severe infections due to MDR organisms. Previously, Infectious Diseases Manager and Director of Pharmacology, Toxicology and Safety Pharmacology at Ferrer Laboratories. Before joining Ferrer in 2008, during 18 years, Director of Drug Discovery Biology and Project Leader at GSK. Prior to joining GSK, Research Associate at the Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, Department of Defense, Bethesda, Maryland, USA. President of the he Spanish Network for the Discovery of New Antibiotics, and Vice-President of the Spanish Network for the Development of Alternative Methods in Animal Experimentation (REMA). Author of over 70 original articles in international journals. Recipient of several distinctions including the Henri Warembourg Faculty of Medicine Medal, awarded by the University of Lille; Medicines for Malaria Venture Project of the Year Awards 2003, 2004 and 2015; and five GSK R&D Recognition Awards.


Speakers:



“Fighting Antibiotic Resistance with Vaccines”

Michael McConnell
Tenured Scientist
National Centre for Microbiology (Spain)

Michael J. McConnell is a Tenured Scientist at the National Centre for Microbiology in Madrid, Spain. Dr. McConnell earned his MD degree and his PhD in Microbiology and Immunology from the University of Michigan Medical School in the U.S. He has more than 15 years of experience in the vaccine field, and his work currently focuses on the development of vaccines and antibody-based therapeutics for the treatment and prevention of infections caused by antibiotic resistant bacteria. Notably, he led the first studies describing experimental vaccines for the prevention of infections caused by the multidrug resistant microorganism Acinetobacter baumannii. Dr. McConnell is a founding partner of Vaxdyn, which develops novel immune-based therapeutics for antibiotic resistant bacterial infections.




“Filling in the Gaps in the MDR Gram-Negative Pipeline”

Michael Michel de Baar
Executive Director Business Development & Licensing Infectious Diseases & Vaccines Ophthalmology & Cardiometabolic Diseases
MSD (United Kingdom)




“Microbial Natural Products, promising sources of novel antibiotics against antimicrobial resistances”

Mª Francisca Vicente
Area Head of Screening and Target Validation
Fundación Medina (Spain)

Evening networking event: Tapas route downtown Seville
20:00 - 22:00
Evening networking event: Tapas route downtown Seville
20:00 - 22:00

Evening networking event: Tapas route downtown Seville
20:00 - 22:00
Evening networking event: Tapas route downtown Seville
20:00 - 22:00

Evening networking event: Tapas route downtown Seville
20:00 - 22:00
Evening networking event: Tapas route downtown Seville
20:00 - 22:00

08:00 - 14:00 - REGISTRATION AND EXHIBITIONS OPENS

09:30 - 14:00 - PARTNERING ONE-TO-ONE MEETINGS

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
FINANCE & INVESTMENT PROGRAM
Italica Auditorium
FINANCE & INVESTMENT PROGRAM
Italica Auditorium
Drivers for success in biotech investment projects: the Spanish case
10:00 - 11:00
Drivers for success in biotech investment projects: the Spanish case
10:00 - 11:00

Spain offers important competitive advantages that consolidate its position as a worldwide investment destination for the biotech industry. A solid scientific base, a highly qualified workforce, state-of-the-art and innovative infrastructures, an integrated healthcare system and strong government support, make the Spanish Biotechnology and Pharmaceutical sector one of the most dynamic and competitive emerging industries on an international level.
In this session we will discuss about the drivers for biotech companies when exploring and deciding investment locations. We will review the Spanish case throughout some of the most relevant investment projects that have chosen our country and have contributed to make Spain a leading location for biotech developments.

Chairperson:



Jaime Montalvo Dominguez de la Torre
Project Management Director
ICEX-Invest in Spain Ministry of Industry, Commerce and Tourism (Spain)

Mr. Montalvo, Project Management Director at ICEX-Invest in Spain, holds a Master Degree in Economics by Universidad Complutense de Madrid. He belongs to the national board of State Economists & Trade Specialists since 1989. Over his 28 years´ experience in the Spanish Public Administration he has held a number of relevant positions at different Government Departments, such as:
- Assistant Deputy Director General for Foreign Investments (Ministry of Industry, Trade and Tourism)
- Chief of Staff of Director General for Trade and Investment (Ministry of Economy) - Deputy Director General for Trade Policy with North and South America (Ministry of Industry, Trade and Tourism)
- Economic and Commercial Counsellor of Spanish Embassies in Malaysia and United Arab Emirates
- Vice-Secretary General of Prime Minister´s Office
- Director General for International Promotion at Spanish Foreign Trade Institute-ICEX

Speakers:



David Villalba Fernández-Ortega
Senior Manager Operations CITRE
CELGENE

David joined Celgene in November 2011 and has been responsible for CITRE's operations and finance since then. It is also CITRE's Biobank Director managing the human samples require to support the research activity of the Spanish R&D site. Previously, he held various positions in PWC and KPMG, as business consultant, where he acquired extensive experience in finance and operations.

He holds a degree in Industrial Organization from the University of Navarra and an Executive MBA from IESE Business School.


Edwin Wagena
Chief Operating Officer
REXGENERO (Spain)




“Spanish Biotech Industry: Main Success Stories”

Ion Arocena
Managing Director
Spanish Bioindustry Association (ASEBIO) (Spain)

Ion Arocena is currently the General Manager of ASEBIO, the Spanish Bioindustry Association. Ion has worked for long as an investment management executive, with deep knowledge of the Spanish and Global Life Sciences market. He studied Biotechnology in Madrid and completed his studies with an executive MBA at EOI Business School, Madrid.

He worked at the Technology Transfer Office of the Universidad Autónoma de Madrid, offering Technology Watch services to SMEs. His next position was at Genoma España, a Government Owned Agency promoting the protection of Intellectual Property and the transfer of such results to companies.

From 2006 to 2015, he was part of the funding team of Suanfarma Biotech SGECR, a venture capital firm, specialized in life science, where he was responsible for the evaluation of investment opportunities.

   

Financial support to innovation in Europe
11:15 - 11:45
Financial support to innovation in Europe

Yu Zhang
Head of Unit, Growth Capital & Innovation Finance
European Investment Bank (Luxembourg)

   

Exhibition area - Closing reception
13:30 - 14:00
Exhibition area - Closing reception

BREAKOUT SESSIONS
​Ronda Room
BREAKOUT SESSIONS
​Ronda Room
Manufacturing
09:30 - 10:30
Manufacturing
09:30 - 10:30

Sponsored by;







Chairperson:



Elena Erroba
Business Development Director
3P Biopharmaceuticals (Spain)

Dr. Erroba is the Business Development Director of 3P Biopharmaceuticals since 2015. Graduated with a degree in Biochemistry and a Ph.D in Science from the University of Navarra, she also holds a Master in Business Administration degree (MBA) from the CEF Business School. She has large experience (more than 12 years) building strong and dedicated worldwide client relationships. She is an executive with an international spirit who has been leading 3P to growth implementing the business development strategies since she joined the company in 2011.

Speakers:

“The role of data analytics in improving biomanufacturing processes”

Robert Zuban
Senior Data Scientist
Sartorius Stedim Biotech (Sweden)

Robert Zuban has a master degree in Chemical Engineering from University of Lund, Sweden. He has mainly worked within R&D pharma with both product and process development, including scale-up activities. Later on he worked as a project manager, managing smaller R&D projects as well as scale up activities. The combination of a scientific and engineering mindset brought him into the field of chemometrics where he has worked as a specialist within innovation and operations within the chemical sector. Today he works for Sartorius Stedim Data Analytics as Senior Data Scientist, where he teaches and inspires clients to use advanced data analytics in their daily work.




“Strategic decision making process for the sizing and implementation of a new single-use 2000L biosimilar plant”

Luisa Amoedo
León Site Director
Mabxience (Spain)

After she obtained a Bachelor Degree in Chemistry by Santiago de Compostela University, she completed her training with a Master in Environmental, Safety and Health at the University of Vigo, a Master in Business Administration at the School of Business, a foundation in collaboration with Vigo University, and a specific Business Development Program at IESE School in Madrid. With more than 20 years of professional experience (14 of them in Biotech), she began her career in a bromatology laboratory. It was in 2004 when she began her development in the world of biotechnology, in one of the leading companies in this sector (Genentech), and in the production of its blockbusters. Since then, she has occupied different positions in production, program management and technology transfer mainly at Lonza Biologics Porriño, a CMO dedicated to the production of monoclonal antibodies and fusion proteins. This experience provided her with a global overview and knowledge of the Biotech business from research process to production for commercial use. In 2013 she joined mAbxience as Technology Transfer Manager, leading the process of transferring to countries as China and Brazil for 1 year. After that, she moved to León to lead the design, construction and startup of the Biotech plant of the company in that city of Spain (León). She is currently the León Site Director at mAbxience.




“Process Intensification using Inline Concentration and Diafiltration on Continuous Bioprocessing”

Martin Glenz
Principal Scientist in Continuous Bioprocessing Group
Pall Life Sciences (Germany)

Studied Biology in Bielefeld, Germany. PhD in Molecular Biology, University Bielefeld. Since 11 years active in the Biopharmaceutical industry. Started as BioPurification Process Specialist in North Germany in 2007. Team Leader BPS in Germany. Principal Scientist in Continuous Bioprocessing Group. Expert in continuous processing (Concentration, Diafiltration, Virus Inactivation, Chromo).

Use of audiovisual and graphic tools to reach your audience in social media
10:45 - 12:00
Use of audiovisual and graphic tools to reach your audience in social media
10:45 - 12:00

Social networks have become one of the most fundamental tools to reach the general public. There are concepts such as innovation and biotechnology that require creative processes to achieve more diffusion. In this conference, the speakers will discuss the importance and the elements that a biotechnology company should utilize for users of social networks in order to better understand their developments.

Moderator:

José Antonio Plaza
Vice-president
Biotech Communicators Association (Spain)

 
Speakers:

Miguel Martínez-Cava
Communication Manager
Pharmamar (Spain)

 

Eduardo Ortíz de Landazuri
Project manager and founder
Visual Thinking Comunicación y Creatividad (Spain)



Jesús López
Communications Manager
IQVIA (Spain)


 

Birthplace of insulin and stem cell research: Toronto
12:00 - 12:45
Birthplace of insulin and stem cell research: Toronto
12:00 - 12:45



"Birthplace of insulin and stem cell research: Toronto"

Did you know that insulin and stem cells were discovered in Toronto? Since then, the Toronto Region Human Health and Sciences Cluster has become a destination for the advancement and commercialization of innovative health technologies and therapies.  In this session you will learn about the talent, research, innovation and commercialization infrastructure that converge in the Toronto Region to bring biotech therapies from bench to bedside and how your business may benefit from connecting into the largest health care market in Canada.

JanWillem Gille
Director Western Europe
Toronto Global (Canada)

As the Director for Western Europe, JanWillem is responsible within Toronto Global for facilitating European Biotech companies to set up successfully in North America. Toronto Global is a Not-for-Profit and our services are free of charge and confidential.

Exhibition area - Closing reception
13:30 - 14:00
Exhibition area - Closing reception

BREAKOUT SESSIONS
Bahia Room
BREAKOUT SESSIONS
Bahia Room
Precision Medicine
10:00 - 11:00
Precision Medicine
10:00 - 11:00

Precision medicine, boosted by the vertiginous development of omics methodologies, is impacting on several relevant topics, such as: more precise disease classification, personalization or even individualization of patient treatments, extensive use of biomarkers in drug discovery and more efficient public prevention measures, including preventive medicine. In this meeting we will highlight recent advances and future perspectives on the application of precision medicine in cancer, rare diseases, drug discovery and new disruptive sequencing technologies.

Chairperson:

María Teresa Molina
Directora General de Investigación y Gestión del Conocimiento
Consejería de Salud (Spain)

Speakers:

"Drug mechanisms of action and biomarkers: a co-development strategy"

Tamara Maes
​CSO, Founder, VP
Oryzon Genomics S.A (Spain)


"Nanopore sequencing: paving the way to personalized genomic medicine"

Richard Compton
VP Commercial Operations
Oxford Nanopore Technologies (United Kingdom)




“Precision Medicine in Heterogeneous Cancers – Challenges and Opportunities"

Christos Hatzis
Associate Professor Director, Bioinformatics, Breast Medical Oncology
Yale Cancer Center (USA)

Dr. Hatzis has 20 years of experience in senior research and management roles in biocomputational techniques, systems biology modeling, genomic analysis and clinical diagnostics. He received his Ph.D. from the University of Minnesota and held several senior research roles in the biotechnology industry. He has been the cofounder of two startup companies specializing in bioinformatics tools development and in clinical diagnostics. Currently, he is an Associate Professor of Medicine at the Yale School of Medicine, where he is involved in the design of biomarker validation clinical studies and development of strategies to translate genomic diagnostic assays to clinical practice. His current research interests focus on developing methods to characterize the genetic and molecular heterogeneity of breast cancer subtypes and its implications on response and resistance to treatment.




"How the use of patient genomic data will transform our public health system: challenges and prospective"

Joaquín Dopazo Blázquez
Area Director
Fundación Progreso y Salud, Junta de Andalucía (Spain)

Dr. Joaquin Dopazo is the Director of the Bioinformatics Area of the Fundación Progreso y Salud, and is in charge of facilitating the introduction of the patient genomic data in the clinical practice within the Andalusian Health System. He has a BSc in Chemistry and a PhD in Biology (University of Valencia, 1989). He was previously leading Bioinformatics teams at the CIPF (Valencia, Spain), CNIO (Madrid, Spain) and Glaxo Wellcome (Madrid, Spain), as well as in some other private and academic institutions. He has published more than 280 papers in international peer-reviewed journals. Dr. Dopazo’s interests revolve around functional genomics, systems biology as well as development of algorithms and software for the analysis of genomic data and its application to personalized and precision medicine.

Exhibition area - Closing reception
13:30 - 14:00
Exhibition area - Closing reception

Public Procurement
Mediterraneo Room
Public Procurement
Mediterraneo Room
Public Procurement of Innovation in Andalucía
09:30 - 13:30
Public Procurement of Innovation in Andalucía
09:30 - 13:30

PUBLIC PROCUREMENT OF INNOVATION IN ANDALUCÍA

9.30. Institutional Inauguration

I. ANDALUSIAN REGIONAL MINISTRY OF AGRICULTURE  INITIATIVES:

10.00 a 11.00.  “Development of innovative analytical methodologies in the agri-food sector with the incorporation of Information and Communication Technologies (ICTs)” Speaker: Juan Antonio Jaén Téllez, Deputy Director-General for Agri-food Inspection and Control of AGAPA

II. ANDALUSIAN REGIONAL MINISTRY OF HEALTH INITIATIVES:

11:00-11:15. "Introduction to Andalusian Public Procurement of Innovation in Health Programme" Speaker: Rafael Solana Lara. General Secretary of Research, Development and Innovation in Health.  Andalusian Regional Health Ministry.

11:15-11:45. "Quick antimicrobial resistance and susceptibility testing (ASURANT)" Speaker: Dr. Jose Miguel Cisneros. Infectious Diseases, Microbiology and Preventive Medicine  Clinical Unit Director. University Hospital Virgen del Rocío de Sevilla. Servicio Andaluz de Salud. Director of the Andalusian Regional Plan for appropriate use of antibiotics (PIRASOA)

11:45-12:15. "Andalusian Liquid Biopsy " Speaker: Prof. José Antonio Lorente. Director of  Andalusian Research and Innovation  in Health Strategy. Scientific Director of Centro de Genómica e Investigación Oncológica GENyO. Granada

12:15-12:45
. "Digital Transformation of Pathology Regional Service (PADIGA) " Speaker: Dr. Marcial García Rojo.  Pathology  Integrated Unit  Director.  Hospital Universitario Puerta del Mar de Cádiz and Hospital Universitario Puerto Real (SAS)

12:45-13:00. "Preliminary Market Consultations next steps" Speaker: José Mª de la Higuera. Andalusian Public Procurement of Innovation in Health Programme Coordinator. Andalusian Health Department

13:00-13:30. Open debate and questions.

Exhibition area - Closing reception
13:30 - 14:00
Exhibition area - Closing reception

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here, or follow this link for more information about cookies.

ACEPTAR
Aviso de cookies